



HHS Public Access

Author manuscript

Biochem J. Author manuscript; available in PMC 2016 July 14.

Published in final edited form as:

Biochem J. 2012 February 1; 441(3): 763–787. doi:10.1042/BJ20111416.

Glycogen and its metabolism: some new developments and old themes

Peter J. Roach¹, Anna A. Depaoli-Roach, Thomas D. Hurley, and Vincent S. Tagliabracci²

Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, U.S.A

Abstract

Glycogen is a branched polymer of glucose that acts as a store of energy in times of nutritional sufficiency for utilization in times of need. Its metabolism has been the subject of extensive investigation and much is known about its regulation by hormones such as insulin, glucagon and adrenaline (epinephrine). There has been debate over the relative importance of allosteric compared with covalent control of the key biosynthetic enzyme, glycogen synthase, as well as the relative importance of glucose entry into cells compared with glycogen synthase regulation in determining glycogen accumulation. Significant new developments in eukaryotic glycogen metabolism over the last decade or so include: (i) three-dimensional structures of the biosynthetic enzymes glycogenin and glycogen synthase, with associated implications for mechanism and control; (ii) analyses of several genetically engineered mice with altered glycogen metabolism that shed light on the mechanism of control; (iii) greater appreciation of the spatial aspects of glycogen metabolism, including more focus on the lysosomal degradation of glycogen; and (iv) glycogen phosphorylation and advances in the study of Lafora disease, which is emerging as a glycogen storage disease.

INTRODUCTION

Glycogen is a branched polymer of glucose that serves as an osmotically neutral means to store glucose in cells in times of nutritional plenty for utilization in times of need [1]. It is present in organisms from bacteria and archaea to humans. Plants synthesize related glucose polymers in the form of starch which is composed of amylopectin, a polysaccharide chemically similar to glycogen, and amylose, which is an essentially unbranched linear polymer of glucose [2,3]. Therefore polymerization of glucose may be a universal mechanism for energy storage in Nature.

The discovery of liver glycogen in 1857 is attributed to Claude Bernard (reviewed in [4]). A century and a half later, several of his original tenets are still accepted and study of glycogen metabolism in the second half of the 20th Century introduced a series of novel biochemical concepts, now engrained in current thinking about biological regulation, and resulted directly in the award of four Nobel Prizes (Carl and Gerty Cori in 1947, Louis Leloir in

¹To whom correspondence should be addressed (proach@iupui.edu).

²Present address: Department of Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0636, U.S.A.

1970, Earl Sutherland in 1971, and Edwin Krebs and Edmond Fischer in 1992; see http://nobelprize.org/nobel_prizes/). Among the scientific advances intertwined with 20th Century research on glycogen are the discovery of NDP-sugars as intermediates in polysaccharide synthesis, reversible protein phosphorylation, the first protein kinases and protein phosphatases, the role of allosteric control of enzymes by ligands, hormonal controls of intracellular enzymes by insulin, and hormonal control by cAMP produced via activation of G-protein-coupled hormone receptors.

The present review does not attempt to be comprehensive, rather it highlights certain major themes and areas of recent progress on eukaryotic glycogen metabolism. The focus is on muscle rather than liver and on synthesis rather than degradation via the phosphorylase pathway. The reader is referred to earlier reviews for additional background [1,5–20]. Wilson et al. [21] provide a recent review of glycogen metabolism in bacteria and yeast. Literature coverage is roughly until July 2011.

GLYCOGEN STRUCTURE

The primary polymerization in glycogen is provided by α -1,4-glycosidic linkages between glucose residues; branchpoints are introduced by α -1,6-glycosidic linkages (Figure 1). Glycogen isolated from biological sources is polydisperse, existing as a population of molecules of different sizes. In addition, branchpoints are not in precisely defined locations, so that molecules of identical mass need not have identical chemical structures. Therefore precise three-dimensional structures of glycogen cannot be determined by the classical approaches of structural biology. The best that can be done to analyse the chemistry of glycogen molecules is to define molecular mass distributions, average chain lengths and average branching frequencies. Nonetheless, important insights into glycogen structure have emerged. A well-accepted model for glycogen structure [22–25] categorizes the chains as inner B-chains, which would normally contain two branchpoints, and outer A-chains, which are unbranched (Figure 1). Chemical analysis of mammalian glycogen suggests that the average chain length is ~13 residues [23,24]. In this model, glycogen would consist of a series of tiers. An important feature is that the outermost tier of any molecule completely formed in this way would contain 50% of the total glucose residues of the molecule as unbranched A-chains (Table 1). Note, however, that only a fraction of these outer-chain glucose residues are accessible to the degradative enzyme glycogen phosphorylase, which stalls four residues from a branch without the intervention of the debranching enzyme [AGL (amylo- α -1,6-glucosidase, 4- α -glucanotransferase)]. It is sometimes noted that branchpoints in glycogen occur every ~12 residues, in apparent contradiction of the idea of B-chains containing two branches per 13 residues. However, if half of the glycogen molecule is composed of unbranched outer A-chains, then the 1 in 12 average number is consistent. It has been calculated that addition of a 13th tier to a glycogen molecule would add an impossible density of glucose residues, making 12 tiers a theoretical maximum [25]. Therefore a full-size glycogen molecule in this model would consist of 12 tiers, for a total of ~55000 glucose residues, a molecular mass of ~10⁷ kDa and a diameter of ~44 nm. In fact, careful analysis of the sizes of glycogen particles present in skeletal muscle by electron microscopy has indicated that few full-size glycogen particles exist and the average diameter is closer to 25 nm or seven tiers [15]. The model described above (Figure 1B) of necessity is

highly stylized, and the actual lengths of the chains, especially the outer chains, would have a major impact on the overall structure and average branching statistics of the population. Indeed, the stochastic nature of glycogen synthesis and the randomness of its metabolism could well mean that individual glycogen molecules deviate significantly from these theoretical formulations, and could be a lot less symmetrical than in the model, with not all tiers being intact for example. Some more detailed structural information has been obtained with simpler oligosaccharides. Polymeric glucose forms helical structures [25]. In amylopectin, parallel helices are thought to form semi-crystalline regions, excluding water and making the polysaccharide quite insoluble. In line with this idea, a crystal structure has been obtained for a 26-residue cyclodextran [26]. In this constrained structure, two antiparallel 13-residue helices are formed, and each is stabilized by a network of intrahelical hydrogen bonds; it is likely that some features of these structures are relevant to those of both natural amylopectin and glycogen.

Individual glycogen molecules are too small to be detected by normal light microscopy. Histochemical staining for glycogen in cells or tissues can therefore only reveal conglomerates of glycogen particles. However, glycogen molecules are large enough to be detected by electron microscopy and have been described as rosette-like β -particles in muscle and larger α -particles in liver [27]. The β -particles would appear to correspond to the type of structures just described. The α -particles seen in liver appear to be formed of aggregates of β -particles, although the chemical basis for the aggregation is not well understood [28,29]. Analysis of gently purified liver glycogen by size-exclusion chromatography techniques suggests a covalent linkage [29]. This conclusion is also supported by stochastic modelling of the assembly of such large glycogen structures [30]. One possibility would be the presence of infrequent extended polyglucose chains, as is seen in amylopectin [2,3]. However, this is an area that clearly deserves further exploration.

Although predominantly composed of glucose residues, glycogen contains other trace constituents, notably glucosamine [31,32] and phosphate. The most studied of these is covalent phosphate. For many years, phosphate in glycogen was thought to be no more than a minor contaminant and the amount of phosphate in purified glycogen was thought to correlate with purity. Not until the early 1980s was the first convincing report that this 'minor contaminant' was an integral part of the polymer [33]. Whelan and colleagues also documented the presence of phosphate in glycogen and postulated that it existed as a C₆-monoester, thereby blocking a potential branchpoint, and as a C₁-C₆ bridging phosphodiester, representing an alternative branchpoint [34,35]. Recent analyses indicate a frequency of glycogen phosphorylation of one phosphate per ~650 glucoses in rabbit skeletal muscle and one per ~1500 residues in mouse muscle glycogen [36,37]. From analysis of phospho-oligosaccharides purified from digested rabbit muscle glycogen, the phosphate has been determined by MS and NMR to exist as C₂- and C₃-phosphomonoesters, probably introduced as side reactions during the action of the normal synthetic enzyme, glycogen synthase [38] (see below). No evidence was found for the presence of C₆-phosphoesters. Excessive phosphorylation of glycogen is associated with a form of epilepsy, called Lafora disease [39–41] (see below). A glycogen molecule undergoes multiple cycles of expansion and contraction. Thus chemical and metabolic insults throughout its lifetime may accumulate and result in an aberrant structure that sometimes escapes normal

metabolism and degenerates into an insoluble deposit, much as other insoluble cellular structures form in various neurological disorders. Whelan and colleagues had proposed exactly this scenario, that the chemical modifications in glycogen might mark the age of the molecule and target the need for its disposal [34]. In fact, in normal aging tissues, even in the absence of overt disease, glycogen-like deposits distinct from normal glycogen have been described in brain, as corpora amylacea [42], and in heart as basophilic degeneration or cardiac colloid [43].

Glycogen forms higher-order assemblages with associated proteins [9,15,18,44,45]. Fischer and colleagues were the first to partially purify from muscle what they termed ‘glycogen particles’ which contained glycogen, several proteins and elements of sarcoplasmic reticulum [46–48]. The particles result from the ability of associating proteins to bind to glycogen, sometimes also to each other and to membranes (Figure 2). Known glycogen-associated proteins are the initiator glycogenin, the metabolic enzymes glycogen synthase, glycogen phosphorylase and the debranching enzyme AGL, and several regulatory proteins including phosphorylase kinase and members of the PP (protein phosphatase) 1G family. In addition, the β -subunit of AMPK (AMP-activated protein kinase) has a CBM20 (carbohydrate-binding module 20) domain [49,50] and has been shown to bind glycogen [51,52]. More recently identified glycogen-associated proteins are laforin [53,54] and Stbd1 (starch-binding domain protein 1)/genethonin 1 [55]. Laforin and Stbd1 also bind to glycogen via a CBM20 domain. A recent proteomics study of gently purified liver glycogen [45] identified most of the above proteins, except phosphorylase kinase and AMPK, as well as some other surprising ones, including ferritin light and heavy chains. Such novel candidates for glycogen binding, of course, require further validation, but virtually all *bona fide* glycogen-associating proteins, until now, have been shown to have a functional role in glycogen metabolism. Notably absent from the list is the branching enzyme, which can obviously interact with glycogen, but which does not appear to form a stable association [56]. The glycogen particle is unlikely to be a complex with a rigorous stoichiometry as is observed, for example, in ribosomes or the pyruvate dehydrogenase complex. Furthermore, there is a strong likelihood of compositional differences between and even within cell types, for example, skeletal muscle where glycogen particles are found in different subcellular locations [57]. Neither can we exclude alterations in composition controlled by physiological conditions.

High-molecular-mass glycogen is insoluble in ethanol, a property frequently used for its purification. In contrast, treatment of cell extracts with TCA (trichloroacetic acid) precipitates protein, but leaves high-molecular-mass glycogen in solution. A portion of the glycogen, however, is precipitated by TCA and has been termed ‘proglycogen’. Lomako et al. [58–60] suggested that proglycogen was a distinct molecular and metabolic entity, possibly with its own metabolic pathways. The matter has been somewhat controversial [10,61–63], and no distinct proglycogen synthase has been identified at the molecular level. A strong argument against the existence of a genetically separate proglycogen synthase comes from the fact that a mouse with the muscle glycogen synthase gene disrupted has undetectable muscle glycogen levels [64]. Also, evidence from a cell model [61] and from analyses of muscles [57] suggested instead a continuum of glycogen species of different sizes with no discrete lower-molecular-mass form. This is not to say that smaller

(proglycogen) particles might not behave differently than larger molecules and some studies make this argument [65]. Unquestioned is the operational definition of proglycogen, reflecting the fact that smaller glycogen particles contain a sufficient proportion of protein to make them TCA-insoluble.

OVERVIEW OF GLYCOGEN METABOLIC PATHWAYS

In mammals, the major deposits of glucose are in skeletal muscle and liver, although many other tissues are capable of glycogen synthesis, including kidney, heart, fat and brain. The precursors for glycogen synthesis are either glucose, derived from newly ingested carbohydrate, or gluconeogenic precursors, such as lactate or alanine, a process sometimes termed 'glyconeogenesis' or the 'indirect pathway' [66]. The latter pathway is carefully reviewed by Agius [17]. The direct pathway requires transport of glucose into cells, by one or more of several GLUTs (glucose transporters) [67]: GLUT1 is widely distributed and provides basal glucose transport; GLUT4 is up-regulated by insulin and is important in insulin-sensitive tissues such as skeletal muscle and adipose tissue; and GLUT2 is prominent in liver and the β -cells of the pancreas and admits glucose based on a positive glucose gradient between the blood and the tissue.

The immediate glucose donor for glycogen synthesis is the activated NDP-sugar UDP-glucose, which is produced by UDP-glucose pyrophosphorylase at the expense of converting UTP into UDP [12] (Figure 3). There is a specialized initiation step whereby glycogenin [68–71] self-glucosylates to form an oligosaccharide primer chain. Via its extreme C-terminus, glycogenin can interact directly with glycogen synthase which is responsible for the formation of the large majority of the α -1,4-glycosidic linkages of glycogen, also utilizing UDP-glucose as the glucosyl donor. The α -1,6-glycosidic branchpoints are formed by the action of the branching enzyme. Yagi et al. [72] described a Nudix hydrolyase that they proposed was relatively specific for UDP-glucose. This UGPPase (UDP-glucose pyrophosphatase), encoded by the *NUDT14* gene, is widely distributed in mammalian tissues and has the potential to modulate glycogen synthesis by setting the level of the glucosyl donor UDP-glucose, even if this would be energetically costly [73]. Whether UGPPase has a physiological role in glycogen metabolism remains an open question. Glycogen is degraded by two distinct pathways. In the first, retrieval of glucose, in muscle to fuel contraction or in liver to provide glucose for export to the bloodstream, is mediated by the actions of glycogen phosphorylase and the debranching enzyme AGL. The immediate products of glycogenolysis are glucose 1-phosphate from α -1,4-linkages and free glucose from α -1,6-linkages. A primary stimulus for hepatic glycogenolysis is nutritional deprivation, with corresponding elevation of counterregulatory hormones such as glucagon [11]. Breakdown of muscle glycogen accompanies exercise, under conditions of increased cAMP and Ca^{2+} [11]. In the second pathway for degradation, glycogen is transferred to the lysosome and hydrolysed to glucose by the lysosomal α -glucosidase [also known as GAA (acid α -glucosidase), acid maltase] [74].

GLYCOGEN SYNTHESIS

Glycogenin

Glycogenin is a self-glycosylating protein that transfers glucose from UDP-glucose first to a tyrosine residue within the protein itself and then forms α -1,4-glycosidic linkages until the oligosaccharide chain is extended to a length of 10–20 residues [75–78]. It is a member of the family 8 retaining glycosyltransferases [79,80]. Humans have two genes that encode glycogenin: *GYG1*, which is more widely expressed, and *GYG2*, whose expression is restricted to liver, heart and pancreas [81]. Rodents, on the other hand, have a single glycogenin gene. There is a report [82] of a patient with mutations in *GYG1*, a nonsense mutation in one allele and a missense mutation, T83M, in the other allele, leading to inactive glycogenin-1. The patient had muscle weakness and had presented with cardiac abnormalities following a bout of exercise. The patient's skeletal muscle completely lacked glycogen, but abnormal PAS (periodic acid–Schiff) staining structures, indicative of polysaccharide, were seen in cardiomyocytes, possibly resulting from expression of the *GYG2* gene.

Structurally, glycogenin is a member of the A-type glycosyltransferase family which is characterized by a single Rossmann-fold domain with additional elaborations of secondary structure that control both donor nucleotide sugar specificity and acceptor specificity [83] (Figure 4A). UDP-glucose is bound in a metal-dependent fashion at the C-terminal ends of the central β -sheet structure (Figure 4B). The metal ion, most likely Mn^{2+} , is co-ordinated by two aspartate residues in the canonical DXD motif, a histidine residue from the protein and two phosphate oxygen atoms contributed by the pyrophosphate group of UDP. The primary function of the metal ion is to stabilize the UDP leaving group during glucosyl transfer. Glycogenin is an example of a retaining glycosyltransferase, in that the α -configuration of the C₁-anomeric carbon is retained in the product. The chemical mechanism of glucosyl transfer in retaining glycosyltransferases generates considerable debate. The simplest explanation for retention of stereochemistry is through the use of a S_N2 double-displacement mechanism and an enzyme-bound intermediate with inverted stereochemistry. However, the identification of an enzyme active-site nucleophile with sufficient catalytic impact has proved elusive, although Asp¹⁵⁹ and Asp¹⁶² seem to play important roles in glycogenin [84]. More recently, there has been some speculation that this class of enzyme achieves retention of configuration by means of an S_Ni-type mechanism where the nucleotide diphosphate serves as the general base to activate the acceptor hydroxy group [85]. The acceptor for glucose transfer by glycogenin is itself, either Tyr¹⁹⁵ in the initial phase of the reaction or the terminal glucose residue of the growing chain subsequently [84,86,87].

The different chemistries of these reactions dictate that there are two phases to the overall process, for two reasons. First, activation of the initial tyrosine hydroxy group and the subsequent 4'-hydroxy groups of glucose as nucleophiles are not energetically equivalent. Secondly, Tyr¹⁹⁵ in the unglucosylated protein is too far away from an active site to permit an intramolecular reaction. The simplest explanation of the available data is that the initial transfer of glucose from UDP-glucose to Tyr¹⁹⁵ occurs through an intermolecular reaction

that switches to an intramolecular reaction as the chain length increases [87]. The initial stages of the glycosyl-transfer reaction appear to follow a processive reaction mechanism where the mono-, di-, tri- and penta-glucosylated species do not accumulate to any significant extent [87]. However, there are slow steps associated with the generation of the tetra- and hexa-glucosylated forms [87]. Subsequent products are more distributive in nature, with all species between seven and sixteen forming a normal distribution. In this manner, glycogenin generates the primer for bulk glycogen synthesis by glycogen synthase.

The association between glycogenin and glycogen synthase is mediated by two mechanisms: (i) association of the glucosyl-primer chain with the active site of glycogen synthase during catalysis; and (ii) protein-mediated association, minimally through a conserved amino acid sequence in the C-terminal domain of glycogenin [88]. The C-terminal 33 amino acids of glycogenin are sufficient for purification of glycogen synthase from tissue extracts and this interaction may be mediated by the relatively conserved sequence motif (WEX₂₋₄DYL/M). However, the data suggest that other sites of association may also exist [88].

Glycogen synthase

In eukaryotes, glycogen synthase is responsible for the bulk synthesis of glycogen by formation of the α -1,4-glycosidic linkages with UDP-glucose as the glucosyl donor. Note that glycogen synthesis in bacteria and starch synthesis in plants utilize ADP-glucose [1]. Eukaryotic glycogen synthase is allosterically activated by glucose 6-phosphate and negatively regulated by covalent phosphorylation. The presence of glucose 6-phosphate overcomes inactivation due to phosphorylation and can restore full activity. This property led to the use of assays of the enzyme in the presence or absence of glucose 6-phosphate to give the ratio of activity with and without glucose 6-phosphate as a surrogate measure of phosphorylation state (see [89]) even though not all phosphorylation sites affect activity. Various modifications of the assay have been used to increase sensitivity to changes in phosphorylation of inactivating sites, such as measuring at low and high glucose 6-phosphate concentrations or altering the UDP-glucose concentration (see, for example, [90]). In the literature, reference to the activity or activation state of glycogen synthase is normally to some version of this assay and, when the enzyme source is a cell or tissue extract, it is taken as an indicator of phosphorylation *in vivo*. It must be recalled that, in the cell, the momentary activity of a glycogen synthase molecule is minimally a function of the concentrations of UDP-glucose, glucose 6-phosphate and glycogen, and its phosphorylation state, of which only phosphorylation is reflected in these standard assays. Measured activity and inferred *in vivo* activity need to be distinguished, although we are all sometimes careless in our usage.

Mammals have two genes that encode glycogen synthase: *GYS1*, which is expressed in skeletal muscle and most other cells capable of glycogen synthesis, and *GYS2*, which appears to be restricted to liver [91,92]. The yeast *Saccharomyces cerevisiae* also has two genes for this enzyme, *GSY1* and *GSY2*, with Gsy2p normally the predominant isoform [93]. Mammalian glycogen synthase was one of the first examples of a multiply phosphorylated enzyme [94] and efforts to identify the responsible protein kinases by several groups in the late 1970s and 1980s contributed significantly to protein kinase

discovery in the days before cDNA cloning. A number of protein kinases were linked to the *in vitro* phosphorylation of subsets of the nine sites of muscle glycogen synthase (Figure 5 and Table 2). The sites are located at the N- and C-termini of the protein. From Ser→Ala mutagenesis, four of the sites, 2, 2a, 3a and 3b, were identified as the most important in determining enzyme activity of rabbit muscle enzyme [95,96]. Similar analysis of liver glycogen synthase, however, suggested a dominant role for phosphorylation of site 2 [97]. The yeast glycogen synthases lack the N-terminal phosphorylation and have three C-terminal sites: Ser⁶⁵⁰ and Ser⁶⁵⁴, that resemble mammalian sites 3a and 3b, and Thr⁶⁶⁷ which is unique to yeast [98]. Phosphorylation of Thr⁶⁶⁷ by the cyclin-dependent kinase Pho85p appears to dominate inactivation ([99], and W.A. Wilson and P.J. Roach, unpublished work). Work on glycogen synthase phosphorylation also led to the concept of hierarchical phosphorylation [100,101], whereby the introduction of one phosphate enables the addition of a second. The prototype for this mechanism was the requirement of prior phosphorylation of glycogen synthase by protein kinase CK2 in order that GSK3 (glycogen synthase kinase 3) could add four successive phosphates per subunit [102] (Figure 5). The molecular basis for the phenomenon is that GSK3 recognizes the sequence -SXXXpS- in glycogen synthase [103], a conclusion that was supported by solution of the three-dimensional structure of GSK3 [104,105]. There are two isoforms, GSK3 α and GSK3 β [106]. In relation to glycogen metabolism, GSK3 α appears to be more important in liver [107] and GSK3 β appears to be more important in muscle [108]. Both GSK3 isoforms are inactivated by phosphorylation of an N-terminal regulatory site by Akt/PKB (protein kinase B) [109]. A second example of hierarchical phosphorylation was provided by the observation that protein kinase CK1 (casein kinase 1) preferred sites with the motif -pSXXXS- in glycogen synthase [110]. A second covalent modification of glycogen synthase has been proposed, namely O-linked attachment of *N*-acetylglucosamine, with the suggestion that this modified enzyme is less sensitive to activation by phosphatases [111]. This idea is still somewhat controversial. More recently, Zhao et al. [112] reported on a proteomic analysis of the acetylation of lysine residues in human liver proteins. Included among the acetylated proteins identified was glycogen synthase, along with glycogen phosphorylase and UDP-glucose pyrophosphorylase. Two modified lysine residues of glycogen synthase, Lys³⁸⁷ and Lys³⁹⁷, are conserved in metazoans, but not in yeast, and are located in the long helix that forms the tetramer interface (see below). Other acetylations are at Lys⁶⁹⁴, Lys⁶⁹⁵ and Lys⁶⁹⁶ close to the C-terminus in a region of lower conservation. The ramifications of this novel finding for the physiological control of glycogen metabolism await further investigation.

Dephosphorylation of glycogen synthase, and other glycogen-metabolizing enzymes, is thought to be mediated by members of a family of glycogen-associated PP1Gs composed of a catalytic subunit (PP1c) bound to a glycogen-targeting subunit [113,114]. To date, seven such glycogen-targeting subunits have been identified by a combination of biochemical and bioinformatic analyses. Three of these targeting subunits have been more extensively studied. The R_{GL} or G_M subunit, product of the *PPP1R3A* gene, is restricted to skeletal and heart muscle [115]. The G_L subunit, coded for by the *PPP1R3B* gene, is primarily expressed in the liver, but is also found in human muscle [116,117]. Its expression in liver is induced by insulin [118]. PTG (protein targeting to glycogen) (or R5), encoded by the *PPP1R3C* gene, is more ubiquitously expressed, and is found in several insulin-sensitive tissues,

including skeletal muscle, liver and fat [119]. PTG was proposed to act as a scaffold, interacting directly with glycogen synthase, glycogen phosphorylase and phosphorylase kinase [120], although other work questions this assessment [121]. Less is known of other family members. PPP1R3D (R6) is widely expressed, with high levels in heart and muscle, and lower levels in liver [122]. PPP1R3E is expressed predominantly in human heart and muscle, but in rat heart and liver [123]. Its hepatic expression was reduced in diabetic rats and the phosphatase activity associated with PPP1R3E was restored by administration of insulin [123]. Munro et al. [123] detected *PPP1R3G* mRNA only in brain, but a recent report described a role for PPP1R3G in liver glycogen metabolism, being paradoxically induced by fasting [124].

Glycogen synthase structure

Like glycogenin, eukaryotic glycogen synthases are retaining glycosyltransferases that utilize UDP-glucose as the nucleotide-sugar donor. However, unlike glycogenin, they are not metal-ion-dependent and possess the other common glycosyltransferase core structure, the GT-B fold [125]. The GT-B fold is characterized by the presence of two Rossmann-fold domains with an interdomain cleft that harbours the active site. It is an interesting evolutionary observation that glycogen phosphorylase, which breaks down glycogen to glucose 1-phosphate, is also a member of the GT-B fold family, suggesting a divergent structural relationship for these enzymes that catalyse opposing reactions [126]. The overall GT-B fold is conserved between bacterial, archaeal and eukaryotic glycogen synthases [125–128]. However, the eukaryotic enzymes differ in oligomeric state, specificity for nucleotide-sugar donor, activation by glucose 6-phosphate and inactivation by phosphorylation.

Each of the distinct properties of the eukaryotic enzymes is associated structurally with sequence insertions or deletions relative to the bacterial and archaeal enzymes (Figure 6). A large insertion of approximately 100 amino acids is present in the C-terminal Rossmann-fold domain and forms the subunit interaction surfaces for the tetrameric eukaryotic glycogen synthases [125]. In addition to this large sequence insertion, a smaller insertion (residues 481–492 in Gsy2p) forms a loop structure that provides the selectivity for UDP-glucose, rather than ADP-glucose, in eukaryotic forms. Regulation by phosphorylation is mediated through N- and/or C-terminal sequence extensions (Figure 5).

Surprisingly, the acquisition of glucose 6-phosphate regulation is not related to addition of structural elements as the binding site is composed of conserved secondary structure. Nor is it related to the glucose 6-phosphate-binding site in glycogen phosphorylase [129], where it is located in the N- rather than C-terminal Rossmann domain, although the conceptual framework for regulation by binding at a subunit interface and the involvement of multiple arginine residues anchoring the phosphate moiety is retained. The glycogen synthase glucose 6-phosphate-binding site is created by a deletion, relative to bacterial and archaeal enzymes, within the loop connecting the N- and C-terminal domains (residues 225–235 in the *Agrobacterium* enzyme, Figure 6) and residue exchanges within the conserved elements of secondary structure. However, the ability to communicate this binding event between subunits requires the tetrameric interface that is generated by the large C-terminal sequence insertion mentioned above. The binding of glucose 6-phosphate within this interface triggers

a large subunit rotation and translocation at the subunit interface, such that the active-site clefts in the individual subunits are now open and accessible for glycogen binding [125] (Figures 7A and 7B). The driving force for this extensive conformational change is provided by relatively few contacts mediated by the glucose moiety of the allosteric activator (Figure 7C). Glucose 6-phosphate is anchored into its binding site through five hydrogen-bonding interactions mediated by the phosphate moiety (Figure 7C), hydrophobic contacts with the faces of the glucose and a hydrogen bond to the 1'-hydroxy group. In contrast, a single hydrogen bond between the 2'-hydroxy group and His²⁸⁰ in the opposing subunit, as well as an interaction between adjacent Asn²⁸⁴ side chains, are the only strong contacts across the subunit interface that appear to stabilize the activated state (Figure 8).

A three-state model for Gsy2p activation was developed mainly on the basis of kinetic data [130]. Dephosphorylated enzyme in the absence of glucose 6-phosphate was in an intermediate basal-activity state. Phosphorylation decreased the activity, whereas addition of glucose 6-phosphate to either phosphorylated or unphosphorylated enzyme generated a high-activity state. Although structural information is available for the basal and activated states of yeast glycogen synthase, as noted above, information about the inhibited state is mostly through kinetic inference using the two available structural models as a basis for extrapolation (Figure 8). Phosphorylation occurs at serine/threonine sites outside the catalytic core (residues 2–630 of Gsy2p) of glycogen synthase to inactivate the enzyme (Figure 5). It is an interesting structural observation that the key regulatory arginine residues between residues 580 and 592 in Gsy2p are grouped on opposing sides of the same α -helix. Arg⁵⁸⁰, Arg⁵⁸³ and Arg⁵⁸⁷ are adjacent to the glucose 6-phosphate-binding site and form interactions with the allosteric activator, whereas Arg⁵⁸¹, Arg⁵⁸⁹ and Arg⁵⁹² lie on the opposing face of the helix and are oriented away from the protein surface [125]. Upon activation, the helices in which these arginine residues reside are pushed apart relative to their positions in the basal state conformation. By inference, we propose that the inhibited conformation positions these same helices closer together, creating a greater conformational tension to overcome in order to achieve an activated state. Evidence for this more closed state comes from two observations. First, mutation of the two arginine residues directed towards the helical interface (Arg⁵⁸⁹ and Arg⁵⁹²) to alanine renders the enzyme in a nearly inactive state (activity ratio of 0.11 [125]). Secondly, an alternative conformational state was observed for our basal-activity structure in which a sulfate, which could be mimicking a phosphate, is positioned between these regulatory helices and, when bound in this position, the helices are 3 Å (1 Å = 0.1 nm) closer than in the other basal-state conformation. Both observations suggest that charge neutralization of the arginine residues not involved in glucose 6-phosphate binding leads to a collapse of the regulatory helices toward each other at this crucial subunit interface, pushing the structure toward a more inhibited state. Like the charge neutralization due to sulfate binding or mutation, binding of a phosphorylated residue from the C-terminal (Gsy2p) or either the N-terminal or the C-terminal (higher eukaryotes) regulatory sequences to these same arginine residues would be expected to promote a similar collapse to the inhibited conformation. Because the conformational changes brought about by glucose 6-phosphate activation only affect the distance between the C-termini and regulatory helices in the opposing subunits, we favour a mechanism whereby the

phosphorylated residues are contributed across this interface from the opposite subunit and form a 'locking strap' to constrain the enzyme to its inhibited state [125].

An interesting property of glycogen synthase is that it remains associated with glycogen even when inactivated, such that both the dephosphorylated and phosphorylated forms of glycogen synthase can be recovered by simple precipitation of glycogen. This tight association with its substrate has led to speculation that the enzyme must possess some type of carbohydrate-binding module, such as those found in glycogen-binding subunits of PP1, laforin or the branching enzyme. However, simple sequence searches have failed to find such a distinct functional domain. When the first glycogen synthase structures were solved, the realization that it had the same protein fold as glycogen phosphorylase led to a thought that, like phosphorylase [131], perhaps glycogen synthase has its carbohydrate-binding sites integrated into its catalytic domain. Indeed, this has now been shown in the *Escherichia coli*, *Pyrococcus abyssi* and yeast Gsy2p enzymes [128,132,133]. These studies have revealed that glycogen phosphorylase and many forms of glycogen synthase retain a glycogen-association site on the surface of their respective N-terminal Rossmann-fold domains that is completely independent of the acceptor binding site within the catalytic cleft (Figures 9A–9C).

Gsy2p from *S. cerevisiae* has four such glycogen-association sites (Figure 9D): one is located on the surface of the N-terminal domain (site-1), two are located on the surface of the C-terminal domain (site-2 and site-3) and one is located near the interdomain cleft (site-4) that leads to the active site [133]. Conservation of amino acids within these glycogen-association sites in higher eukaryotes suggests that the mammalian enzymes possess these same sites. Mutational data, as well as yeast strain complementation experiments, indicate that all sites contribute to efficient utilization of glycogen as a substrate. However, site-4 appears to be unique in its ability to significantly affect the capacity of Gsy2p to utilize smaller oligosaccharides, such as malto-octaose, as an alternative acceptor substrate [133]. These findings support the idea that glycogen synthase integrates its carbohydrate-binding surfaces into the catalytic domain of the enzyme and these sites contribute to the high catalytic efficiency of glycogen synthase towards glycogen as its substrate.

It is likely that eukaryotic site-1–site-3 keep the enzyme tightly coupled to its substrate whether the enzyme is active or not, whereas site-4 serves a role in the proper positioning of the acceptor end within the active-site cleft, which apparently has a relatively low affinity for the acceptor end. This strategy solves the problem of rapid binding and release of actively extending chains, not requiring complete dissociation from glycogen to reset the position of the acceptor within the active site. It also increases the local concentration of non-reducing ends at or near the active site such that the lower affinity of the acceptor site does not negatively affect the overall efficiency of catalysis.

Díaz et al. [132] recently suggested that binding at accessory sites on the enzyme surface contributes to the processivity of glycogen synthase for chain elongation. Although this may be true, processivity towards a heterogeneous substrate such as glycogen is difficult to assess, since there are many non-reducing ends within a single glycogen particle where

catalysis can be directed without dissociation from the particle itself. The currently available data, including those of Baskaran et al. [133], would support this definition of processivity. However, there are no unequivocal methodologies currently available to assess the more strict definition of processivity where glycogen synthase remains associated with a single acceptor chain for multiple rounds of catalysis. The new elongation assay utilizing malto-octaose as a substrate demonstrates a distributive mechanism for elongation of this substrate [133]. Thus processivity with respect to glycogen must be a function of the additional points of contact between the enzyme and this complex substrate.

Catalytic mechanism and introduction of phosphate into glycogen by glycogen synthase

As mentioned for glycogenin, the chemical mechanism underlying catalysis in retaining glycosyltransferases remains an enigma. This is especially true for glycogen synthases. Unlike metal-dependent enzymes such as glycogenin, where a metal ion is the primary means through which the UDP leaving group is stabilized, glycogen synthases are metal-ion-independent and rely on hydrogen bonds to amino acid side chains and main-chain atoms to provide charge stabilization of the UDP product (Figure 10). The available nucleotide-bound structures suggest that these roles are filled by conserved arginine and lysine residues (320 and 326 respectively in Gsy2p) and the helical dipole created by the N-terminus of the helix (residues 513–521 in Gsy2p) immediately adjacent to the conserved glutamate residue (Glu⁵⁰⁹) that is strongly implicated in the glycosyl-transfer mechanism [128,134]. A number of catalytic roles have been proposed for this residue, including charge polarization of Lys³²⁶ for UDP stabilization, charge stabilization of the oxonium ion intermediate in an S_N1/S_Ni mechanism, proper positioning of the glucosyl-donor sugar and as the catalytic nucleophile in an S_N2 mechanism [126–128,134]. Whatever the precise role of this residue in the catalytic chemistry, it is clear that its presence in the active site contributes at least 10⁴ towards the catalytic power of the enzyme and thus must be considered a nearly essential catalytic contributor.

Independent of the precise catalytic roles that active-site amino acids play in catalysis, the stereochemistry of the reaction dictates that the acceptor substrate is directed towards the same face of the glucosyl moiety from which the UDP leaving group departed. Thus the ability of the C-1 carbon atom to release the leaving group and undergo nucleophilic attack is an essential component of the reaction mechanism. However, there are other atoms of UDP-glucose that can undergo nucleophilic attack, including the phosphorus atoms in the diphosphate moiety. It has been proposed that the trace levels of phosphate found in glycogen arise from the inherent reactivity of the β -phosphate of UDP-glucose, leading to the incorporation of glucose-phosphate esters into glycogen [38].

Whelan's group first reported an enzymatic activity from rabbit skeletal muscle that was capable of transferring the β -phosphate of UDP-glucose to glycogen [35]. However, the enzyme was never characterized at the molecular level. To assay and purify the proposed glycogen:glucose-1-phosphate transferase, Tagliabracci et al. [38] synthesized [β -³²P]UDP-glucose and demonstrated transfer of the β -phosphate from UDP-glucose to glycogen by a mouse muscle extract, but unexpectedly discovered that a muscle extract from a *Gsy1*^{-/-} mouse {MGSKO (muscle-specific glycogen synthase-knockout) mouse [64]}, that lacks

glycogen synthase, did not catalyse this reaction. Purified glycogen synthases could also phosphorylate glycogen *in vitro*, with one phosphate introduced for every ~10000 glucose residues. This reaction might be viewed as an enzymatic error, not unlike those that occur during DNA and RNA biosynthesis [38]. The chemical mechanism for transfer of phosphate from UDP-glucose to the C-2 and C-3 hydroxy groups in glycogen awaits experimental confirmation, but it was speculated that it involves the formation from UDP-glucose of cyclic glucose phosphates (Figure 11), first described over 50 years ago by Paladini and Leloir [135]. Rarely, within the active site of glycogen synthase, the 2' or 3' hydroxy groups of UDP-glucose would spontaneously form glucose 1,2-cyclic phosphate or glucose 1,3-cyclic phosphate through nucleophilic attack of the respective hydroxy groups on the β -phosphate of UDP-glucose. At this point, the standard mechanism of glycogen synthase would operate, with attack by the activated C-4' hydroxy group of the terminal glucose at the C-1 position of the cyclic phosphate, opening the ring to form a phosphoglucose that is added to the growing chain.

Naturally occurring mutations of glycogen synthase and glycogen storage disease 0

Naturally occurring mutations in both *GYS1* and *GYS2* have been detected in humans. Mutation of *GYS2*, which causes hepatic glycogen deficiency, is better documented, and was named glycogen storage disease 0 (OMIM ID #240600). Patients have relatively mild symptoms, postprandial hyperglycaemia and fasting hypoglycaemia, consistent with the observed deficit in liver glycogen stores [136]. Hepatic glycogen synthase activity is reduced, consistent with the analysis of a number of the naturally occurring *GYS2* mutations by expression in COS cells [137]. A mouse model, LGSKO (liver-specific glycogen synthase-knockout) mice, in which the *Gsy2* gene is disrupted, reproduces much of the phenotype of the human disease [138]. The animals have mild fasting hypoglycaemia, but dispose glucose less well in a glucose-tolerance test. Fed animals have lower capacity for exhaustive exercise than their wild-type littermates, but the difference is lost after fasting. The mice have elevated basal gluconeogenesis and are predisposed to transition to the fasted state. Liver glycogen is therefore significant for normal blood glucose homeostasis.

Loss-of-function mutations in muscle glycogen synthase have been reported in two families [139,140]. The disease has been designated muscle glycogen storage disease 0. In the first study [139], three siblings were identified with homozygous R462X mutations in *GYS1*. One sibling died of cardiac arrest at age 10.5 years and a second exhibited poor exercise performance and cardiac abnormalities at 11 years of age. Glycogen synthase and glycogen were absent from muscle. In the second case [140], an 8-year-old patient collapsed and died during exercise and was found to have a homozygous two-base deletion in exon 2 of *GYS1*. Many of the symptoms are consistent with cardiac problems observed with MGSKO mice in which *Gys1* is disrupted [64,141]. In crosses of *Gys1*^{-/+} mice, 90% of the homozygous progeny died perinatally and had abnormal heart development. The surviving MGSKO mice had normal exercise capacity [142], normal lifespans with no overt cardiac symptoms and, paradoxically, enhanced glucose disposal in glucose-tolerance tests. It is likely that substantial developmental and metabolic differences between mice and humans underlie the observed discrepancies in phenotype between species. For example, in humans, it is possible that the perinatal mortality seen in mice can be delayed into early childhood. In any event,

this work underscores the possibility that *GYS1* mutation may be an under-recognized cause for unexplained cardiac problems and deaths in newborns and young children.

In horses, PSSM (polysaccharide storage myopathy) has been recognized for many years as a debilitating glycogen storage disease prevalent in several genetically diverse breeds [143]. Breeding for desired traits in horses has also led to the concomitant accumulation of undesired genetic characteristics. PSSM is associated with excessive glycogen accumulation in muscle; symptoms vary widely, but can be very severe, leading to the inability of the animal to rise from a lying position. Recently, a mutation responsible for PSSM in multiple horse breeds was identified as an R309H-coding mutation in *GYS1* and was associated with increased muscle glycogen synthase activity in the absence of the allosteric activator glucose 6-phosphate, to generate a constitutively activated form of the enzyme. From inspection of the Gsy2p structure, this mutation is quite distant from the glucose 6-phosphate-binding site, but does occur at the interface between the catalytic domain and the long α -helices involved in subunit–subunit interactions. The mutation may therefore indirectly favour transition to the activated state, but more specific experiments would be needed to confirm this idea.

REGULATION OF MUSCLE GLYCOGEN SYNTHESIS

Rate-determining steps

Glycogen synthesis normally occurs after a meal, when blood glucose and insulin levels are elevated, or after exercise to restore depleted glycogen reserves. In muscle, a major issue is whether the rate of glycogen synthesis is determined by the rate of glucose entry into the cell or the activity of intracellular enzyme(s). In the terminology of MCA (Metabolic Control Analysis) [144], which steps have greatest flux control? Relatively few proteins are involved in the glycogen synthetic pathway (Figure 3) and the main candidates to control muscle glycogen synthesis are GLUT4, hexokinase and glycogen synthase. The other enzymes, i.e. phosphoglucomutase, UDP-glucose pyrophosphorylase, glycogenin and branching enzyme, do not appear to be either strongly regulated or rate-determining under normal circumstances. For many years, it was thought that dephosphorylation and activation of glycogen synthase by insulin was the dominant factor, following from the seminal study of Villar-Palasi and Lerner [145]. This fundamental observation has been reproduced many times in animal- and cell-based experiments, and there is a good consensus on this point. When specialized glucose transporters were identified, attention focused also on glucose transport, especially with the finding that insulin promoted GLUT4 translocation to the plasma membrane in muscle [67]. Several mouse models have been constructed in which different components of the glycogen biosynthetic pathway have been mutated. The resting muscle glycogen content of a fed mouse provides a key primary index of the ability to synthesize glycogen under physiological conditions of insulin action. One of the earliest challenges to the primacy of glycogen synthase control came from transgenic overexpression of GLUT1 or GLUT4 in skeletal muscle which caused significant overaccumulation of glycogen [146,147]. However, muscle-specific knockout of GLUT4 paradoxically also led to elevated muscle glycogen [148]. The phenotype is ascribed to a variety of secondary effects in this mouse, including activation of PPIGs with concomitant activation of glycogen synthase, and increased hexokinase leading to elevated glucose 6-phosphate. The complexity

of the phenotype made it difficult to assess the contribution of glucose transport to glycogen storage. Mice heterozygous for GLUT4-knockout, however, did exhibit decreased muscle glycogen levels [149]. Other mouse models have addressed glycogen synthase. Transgenic overexpression of glycogen synthase with two key inactivating phosphorylation sites (2a and 3a) disabled (GSL mice) led to hyperaccumulation of glycogen in muscle [150]. More subtle genetic manipulation of glycogen synthase activity was achieved by overexpression [151] or knockout [152,153] of the gene encoding the PP1 glycogen-targeting subunit R_{GL} so as to modify the phosphorylation state of glycogen synthase. Overexpression of R_{GL} increased muscle glycogen approximately 3-fold, whereas the absence of R_{GL} reduced muscle glycogen to 10% of wild-type. However, in these mice, the phosphorylation of both glycogen synthase and phosphorylase was modified. In humans, a common nonsense mutation in the *PPP1R3A* gene, which encodes R_{GL} , was identified in 1.4% of the white population in the U.K. [154]. The mutation resulted in a truncated R_{GL} protein and a decrease in muscle glycogen accumulation. A corresponding mutation engineered in mice reduced muscle glycogen by 50% and caused mis-targeting of R_{GL} . In mice lacking the PTG PP1-targeting subunit, a ~30% reduction in muscle glycogen was observed [155]. An earlier study [156] had reported that homozygous disruption of PTG was lethal, but this result appears in contradiction to the more recent data. Other investigations sought to manipulate glycogen synthase phosphorylation via protein kinases. This approach is *a priori* complex, since multiple protein kinases can phosphorylate glycogen synthase and multiple sites can influence activity (Table 2). Muscle-specific disruption of the gene encoding *GSK3 β* resulted in a 2-fold increase in glycogen accumulation, with an increase in glycogen synthase activation by insulin, but no effect on glucose transport; the animals had improved glucose disposal and insulin-sensitivity [108]. Taken together, the preceding results with mouse models suggest that genetic modulation of either glucose transport or glycogen synthase activity is capable of affecting muscle glycogen stores.

Shulman and colleagues have addressed this question using a combination of *in vivo* NMR and MCA [157–159]. Their conclusion was that, within the formalism of MCA, flux control was concentrated at the stage of glucose transport. They argue that glycogen synthase activation via dephosphorylation serves not to increase the metabolic flux to glycogen, but rather to allow a higher glycogen synthetic rate without elevation of glucose 6-phosphate levels [160]. It was pointed out many years ago that there is limited solvent capacity in cells and that it is therefore necessary to minimize metabolite concentrations [161]. Another MCA analysis of insulin-stimulated glycogen synthesis in rat muscle indicated flux control distributed between transport and synthesis [162]. So, where are we in resolving this issue? The different experimental approaches have their advantages and drawbacks. Genetically modified mice have the power of any genetic system, but suffer from the possibility of adaptive responses to the gene modifications; a kind of biological Heisenberg uncertainty principle, if you will. The elegance of non-invasive analysis of glycogen metabolism by NMR has to be balanced with its limitations [163], which include sensitivity and inability to address spatial heterogeneity. The application of MCA in complex animal models is also based on necessarily simplistic assumptions. We would argue that regulation, defined as an evolved mechanism to modify activity, of both glucose transport and of glycogen synthase

can contribute to the rate of glycogen accumulation, possibly to different extents that may vary under different circumstances [164].

Mechanism of glycogen synthase activation by insulin

More challenging has been the effort to determine which of the *in vitro* protein kinases and/or phosphatases mediate the activation of glycogen synthase by insulin (Figure 12). GSK3, whose action potently inactivates glycogen synthase *in vitro* by phosphorylation of four C-terminal sites [165], has long been considered an important candidate to regulate glycogen synthase. Insulin controls GSK3 activity by promoting phosphorylation of its N-terminal inhibitory phosphorylation site via the Akt/PKB pathway, by a well-established mechanism [166,167]. Insulin thus inactivates GSK3, leading to decreased phosphorylation at its target sites in glycogen synthase due to phosphatase action. Muscle-specific knockout of GSK3 β in mice increased glycogen levels and potentiated insulin-mediated activation of glycogen synthase [108]. Conversely, overexpression of GSK3 β in muscle resulted in reduced glycogen accumulation and reduced the glycogen synthase activation state [168]. Earlier studies had suggested that insulin caused dephosphorylation of both N- and C-terminal phosphorylation sites of glycogen synthase [169,170]. The argument was therefore made that insulin must promote dephosphorylation of non-GSK3 sites by other mechanisms (see, for example, [12]). Possibilities would include inactivation of a site 2 kinase, for which there are numerous candidates (Table 2), or activation of a phosphatase, probably of the PP1G family. Knockout of the gene encoding either R_{GL} [152,153] or PTG [155] reduced basal glycogen synthase activity and glycogen accumulation, but did not disable insulin-mediated activation of glycogen synthase. If a phosphatase is involved, it must involve a different regulatory subunit. Another potential complication is redundancy of protein kinases for a given site. For example, in COS cells, sites 3a and/or 3b of glycogen synthase can be phosphorylated by a mechanism independent of GSK3 [95]. There are three candidates from *in vitro* experiments, a DYRK (dual-specificity tyrosine-phosphorylated and -regulated kinase) family kinase [171], p38 β [172] and PASK [PAS (Per/Arnt/Sim) domain-containing protein kinase] [173]. Some of the uncertainty may have been resolved by the study of McManus et al. [174] who made knockin mice in which either or both GSK3 α and GSK3 β had their inhibitory N-terminal phosphorylation sites (Ser²¹ and Ser⁹ respectively) mutated to alanine. Surprisingly, muscle glycogen levels were unaffected in the double-knockin homozygous mice in which GSK3 is constitutively active. Basal glycogen synthase activity was also unchanged, as was phosphorylation of key GSK3 sites, Ser⁶⁴¹ and Ser⁶⁴⁵, but insulin-stimulated activation of glycogen synthase was suppressed. The authors argue that the results prove not only that GSK3 (in particular GSK3 β) is the primary means by which insulin activates muscle glycogen synthase, but also that no other protein kinases, phosphatases, or phosphorylation sites are involved unless they too are controlled by GSK3. Perhaps the latter conclusion is a little strong since insulin did activate glycogen synthase in GSK3 β muscle-specific knockout mice without compensatory changes in GSK3 α protein levels or insulin-induced phosphorylation [108]. Therefore there may still be room for GSK3-independent controls of glycogen synthase activity by insulin, but the GSK3-knockin mouse models make a strong case for the importance of GSK3 in insulin signalling to glycogen synthase.

Mechanism of glycogen synthase control by exercise

Exercise depletes glycogen which must subsequently be replenished, requiring activation of glycogen synthesis (Figure 12). Depending on the experimental conditions, both inactivation and activation of glycogen synthase have been observed in response to exercise [175,176]. Furthermore, activation has been observed both during exercise and after its cessation [175]. Activation of glycogen synthase could be considered paradoxical since this is, overall, a period of glycogen utilization. Several rationalizations can be advanced: (i) activation could 'prime' glycogen synthase for rapid glycogen synthesis once contractile activity lessens; (ii) other factors besides phosphorylation may prevail to avoid glycogen synthesis and 'futile cycling' of glycogen; and (iii) glycogen is actually synthesized and utilized during exercise [177]. Nielsen and Richter [175] have emphasized how various negative and positive signals elicited during exercise must be integrated to determine glycogen synthase activity. Still, the exact mechanism for how exercise controls glycogen synthase phosphorylation is not yet clear, although there is probably a consensus that it differs significantly from insulin-mediated regulation. First, exercise-induced activation of glycogen synthase occurs in muscle-specific insulin-receptor-knockout mice [178]. Secondly, exercise activation of glycogen synthase is normal in the GSK3-double-knockin mice described above [174]. Knockout of the PP1 glycogen-targeting subunit R_{GL} in mice does block activation of glycogen synthase by exercise or *in situ* electrical stimulation, suggesting a role for the phosphatase [151]. How R_{GL} is regulated is not known. An earlier model had proposed that PKA (protein kinase A), activated by adrenaline (epinephrine), phosphorylates R_{GL} and causes its dissociation from the glycogen particle [179]. However, during exercise, the PKA pathway is likely to be activated, which would decrease phosphatase activity in this model.

The relationship between glycogen synthase phosphorylation and activity during muscular activity is complex and exemplifies the notion that inhibitory and activating signals can converge. It has been observed that exercise causes both phosphorylation of sites 2 and 2a, correlating with decreased activity, whereas, upon more prolonged activity, sites 3a and 3b are dephosphorylated, resulting in a net activation [176,180]. Dephosphorylation of sites 3a and 3b could result from the action of R_{GL}-PP1c, as described above. Site 2, *in vitro*, is a substrate for multiple protein kinases (Table 2), several of which could conceivably be activated under conditions of muscle contraction. Phosphorylase kinase and AMPK are known to associate with glycogen and have well-established mechanisms for activation during exercise. Phosphorylase kinase is activated by Ca²⁺ and PKA. PKA is activated by cAMP, whose level is likely to be increased under conditions of glycogenolysis. Note also that phosphorylation of a C-terminal PKA site, site 1b, may have a function in the translocation of glycogen synthase (discussed below). Furthermore, CAMKII (Ca²⁺ / calmodulin-dependent protein kinase II) is also activated by Ca²⁺.

Attention has been paid recently to the possible role of AMPK as a site 2 kinase. AMPK, whose activity increases with depletion of the adenylate pool for ATP, is thought to be a monitor of cellular energy status [181] and is indeed activated by muscular activity [182]. AMPK phosphorylates glycogen synthase *in vitro* [183], and disruption of the gene encoding the $\alpha 2$ -subunit, but not the $\alpha 1$ -subunit, of AMPK resulted in decreased basal phosphorylation of glycogen synthase at site 2 + 2a by ~60% and increased its activation

state [184]. AICAR (5-amino-4-imidazolecarboxamide riboside), an oft used, although relatively non-specific, activator of AMPK, caused a modest increase in site 2 phosphorylation that was not seen in the $\alpha 2$ -knockout muscle [184]. The β -subunit of AMPK, as noted, contains a CBM20 domain that allows it to bind glycogen, certainly *in vitro* [51,52,185]. There is some controversy over the stability of the association and its effects on activity. Stapleton and colleagues attempted to isolate glycogen using relatively gentle methods and could not document co-purification of the β -subunit [45,186]. They had previously failed to show inhibition of AMPK activity by glycogen [52]. However, the study of McBride et al. [185] provides fairly compelling evidence for inhibition of AMPK activity *in vitro* by glycogen, although they note some variability between glycogen preparations. Their bovine liver glycogen inhibited half-maximally at 30 mM glucose equivalents. Smaller oligosaccharides also bound and some could inhibit depending on their structure. For example, linear oligosaccharides such as maltohexaose or maltoheptaose bound, but did not inhibit, AMPK, whereas synthetic oligosaccharides containing an α -1,6-linkage were effective inhibitors in the 100–200 μ M range. This observation led McBride et al. [185] to propose that AMPK bound to extended outer chains of glycogen would be active and able to phosphorylate and inactivate glycogen synthase, whereas glycogen with outer chains degraded by phosphorylase, would have more exposed α -1,6-linkages that could inhibit AMPK, leading to activation of glycogen synthase. Of course, one weakness in this hypothesis is that, *in vivo* in the presence of debranching enzyme AGL, phosphorylase-limit outer chains would surely have a fleeting existence. Also, site 2 phosphorylation alone cannot fully inactivate glycogen synthase. The broader notion, that AMPK acts as a sensor of glycogen, is, however, appealing. It could help to explain the inverse correlation between glycogen synthase activation state and glycogen level that goes back to the early study of Danforth [187]. Particularly in muscle, there is a correlation between increased AMPK phosphorylation (and presumably activity) and decreases in glycogen level caused by exercise [182] or genetic manipulation [141]. In liver, matters may be less clear since depletion of glycogen in the LGSKO mice, if anything, decreased AMPK phosphorylation [138]. The concept of glycogen level and concentration is itself a particularly difficult one, as acknowledged by McBride and Hardie [188]. Even without invoking differences in affinity for particular oligosaccharide structures, the surface of a large glycogen particle is likely to be very different than that of a smaller one, presenting a different local concentration, if you will, of chains to inhibit or not inhibit AMPK. Future work will require clever experiments to test this intriguing hypothesis.

A rather different connection between AMPK and glycogen comes from study of Hampshire pigs [189] and *PRKAG2* (AMPK γ^2 non-catalytic subunit) mutations in humans [190] which cause massive overaccumulation of glycogen in muscle and heart respectively. In the pigs, excess glycogen has a deleterious effect on meat quality. In humans, it causes *PRKAG2* cardiomyopathy. The mutations are in the γ^3 and γ^2 subunits of AMPK respectively, and, although there has been some debate, it appears that the mutations are effectively gain-of-function [190]. That such mutations cause increased glycogen storage cannot be easily reconciled with glycogen synthase phosphorylation at site 2. In addition, in some studies, AMPK activation by exercise correlates with activation of glycogen synthase [151,191]. It is possible that a different function of AMPK is involved, such as its role in autophagy, as

discussed below, or its stimulation of glucose transport in muscle. It remains to be established whether AMPK is really a predominant glycogen synthase site 2 kinase.

Allosteric compared with covalent control of glycogen synthase

Since glycogen synthase is regulated by both phosphorylation and allosteric activation by glucose 6-phosphate, the relative importance of these mechanisms has been much discussed, especially for liver where glucose 6-phosphate is believed to play an important role in driving glycogen synthesis [7,14,17]. Pederson et al. [130] used an alanine-scanning mutagenesis approach to identify basic residues of yeast Gsy2p involved in activation by glucose 6-phosphate. Two mutant enzymes were identified that, *in vitro*, were unaffected by glucose 6-phosphate; one retained inactivation by phosphorylation and the other was unaffected by phosphorylation. The mutations were of arginine residues in the highly conserved arginine cluster (Figure 5) that is involved in binding glucose 6-phosphate and setting the activity state of the enzyme (Figures 7 and 8). Expression of the unregulated mutant Gsy2p in yeast resulted in hyperaccumulation of glycogen, whereas the mutant that retained phosphorylation control accumulated less glycogen than wild-type enzyme [192]. The study provided evidence for the importance of glucose 6-phosphate in normal glycogen synthesis *in vivo* and also affirmed the relevance of phosphorylation in the absence of glucose 6-phosphate control [192]. A more recent discussion of mammalian systems began with the work of McManus et al. [174], discussed above, on the double-knockin homozygous mice with constitutively active GSK3 in which glycogen levels were normal. Bouskila et al. [193] suggested that, in these double-knockin mice, glucose 6-phosphate control might be the key reason for the normal glycogen accumulation. Hanashiro and Roach [194] had transferred the glucose 6-phosphate-desensitizing mutations studied in yeast Gsy2p to mammalian glycogen synthase and Bouskila et al. [193] refined the analysis to identify R582A and R586A as point mutations that conferred insensitivity to glucose 6-phosphate activation, sensitivity to phosphorylation and the ability to be normally expressed in mammalian cells. A *Gys1*-knockin mouse encoding the R582A mutation was then constructed. Muscle glycogen levels were ~50% of wild-type, demonstrating that glucose 6-phosphate activation of glycogen synthase plays an important role in glycogen metabolism. This result, in fact, is quite similar to what was observed in yeast [192]. The muscle from the R582A mice had elevated glucose 6-phosphate and UDP-glucose levels, consistent with diminished flux towards glycogen, and *ex vivo* analyses of muscles indicated reduced insulin-stimulated glycogen synthesis. Bouskila et al. [193] concluded that insulin stimulation of glycogen synthesis in muscle is driven predominantly by elevation of glucose 6-phosphate, not glycogen synthase dephosphorylation. Hunter et al. [195] reported that AICAR-induced glycogen synthesis was abolished in the R582A mice, arguing that glucose 6-phosphate was driving glycogen accumulation. These studies raise interesting questions. It would be useful to revisit the role of phosphorylation control using knockin of glycogen synthase mutated at site 2 and/or 3a to see whether the results mimic the earlier less sophisticated GSL mouse models that used transgenic overexpression [150].

SPATIAL ASPECTS OF GLYCOGEN METABOLISM

Heterogeneity of glycogen stores in cells and tissues

Glycogen is usually described as primarily cytosolic. In typical biochemical fractionations of extracts of tissue or cells, the bulk of the glycogen remains in a low-speed supernatant after centrifugation, although some is in the pellet, depending on the biological source and metabolic conditions. Glycogen particles are large enough that high-speed centrifugation of the low-speed supernatant can sediment them into a high-speed pellet, together with membranous structures. Although it is possible and even likely that small-molecule metabolites are not homogeneously distributed within cells, it is especially easy to make the case with glycogen, since it can be visualized by electron microscopy as discrete particles, each one a potentially autonomous metabolic machine. In skeletal muscle, cellular localization leads to the definition of distinguishable pools of glycogen granules, sarcolemmal, intermyofibrillar and intramyofibrillar [57,196]. Graham and colleagues have pioneered efforts to quantify these subcellular pools (reviewed in [15,19]), and evidence is emerging that different pools may have different metabolic behaviours [197,198]. A further level of heterogeneity enters when one considers entire tissues. Different muscle fibre types, which can be intermingled in any given muscle, can have different metabolic regimes [199], glycogen metabolism being more important in fast twitch type II fibres. In the liver, periportal and perivenous hepatocytes have significantly different metabolic capacities [200], including differences in the metabolism of glycogen [201]. Obviously, measurements of glycogen by gross biochemical or NMR methods cannot address such heterogeneity.

Translocation of metabolic enzymes during glycogen synthesis

In liver, it is generally accepted that glucose entry into cells is driven by the concentration gradient between the blood and the hepatocyte, based on the kinetic properties of the high- K_m GLUT2 [67]. Unlike the hexokinase of muscle, the liver glucokinase (hexokinase IV) is not inhibited by its product glucose 6-phosphate, but by a separate regulatory protein [GKRP (glucokinase regulatory protein)] [202]. Glucokinase, under basal glucose conditions, is sequestered in the nucleus where it is bound to GKRP and is held inactive [202]. Acute activation of glucokinase involves its glucose-induced translocation from the nucleus to the cytosol. Guinovart and colleagues have championed the idea that hepatic glycogen synthase also translocates upon exposure of hepatocytes to glucose towards the cell periphery, where new glycogen is synthesized at the site of glucose entry (reviewed in [14]). Glucose 6-phosphate appears to be critical to the translocation process as well as being a direct activator of glycogen synthase.

Hers and colleagues (reviewed in [203]) many years ago proposed a mechanism whereby glycogen phosphorylase and synthase phosphorylation states were controlled in an interdependent fashion in the liver. Central to this hypothesis was allosteric inhibition of glycogen synthase phosphatase by the phosphorylated and active form of phosphorylase. Thus activation of glycogen synthase by a glycogenic stimulus would only be enabled once phosphorylase was first inactivated. Cohen and colleagues revisited this concept armed with more modern understanding of the nature of the phosphatases likely to be involved [116,117]. A predominant glycogen synthase phosphatase in liver consists of the PPI

catalytic subunit in association with the G_L glycogen-targeting subunit [116,117]. Armstrong et al. [121] localized the phosphorylase interacting sequence to the C-terminal 16 amino acids of G_L and Kelsall et al. [204] showed that mutation of Tyr²⁸⁴ to phenylalanine disrupted binding to phosphorylase. Kelsall et al. [205] went on to produce Y284F-knockin mice and demonstrated that liver glycogen was increased modestly, but both glycogen synthase and phosphorylase activities were significantly increased. *In vitro* assays showed that thiophosphorylase was unable to inhibit the glycogen synthase phosphatase activity of mutant G_L-PP1c. There was an improvement in glucose disposal in the Y284F mice, especially in males, leading to efforts to target interference of the G_L-phosphorylase interaction as a therapeutic approach for Type 2 diabetes [206].

Translocation of glycogen synthase has also been observed in other cells. Cid et al. [207] showed that the muscle glycogen synthase isoform was localized in the nucleus in several cell types, including primary human myoblasts, when glucose was low or absent, but was cytosolic in punctate structures in the presence of glucose. Interestingly, phosphorylation does not appear to be relevant to this nuclear localization whereas the arginine-rich cluster is important. In *S. cerevisiae*, glycogen synthase localization correlated strongly with cellular glycogen content [208], changing from a uniform distribution in the cytoplasm when glycogen was abundant to discrete well-defined spots when glycogen was scarce. In a strain lacking glycogenin, and hence unable to synthesize glycogen, Gsy2p was nuclear, echoing the results discussed above. In yeast, however, mutation of the arginine-rich cluster did not affect nuclear localization. Other studies have linked glycogen synthase phosphorylation to subcellular distribution. In 3T3-L1 adipocytes, Ou et al. [209] reported that insulin caused activation of glycogen synthase accompanied by a shift from a diffuse distribution to punctate cytosolic structures. Other correlations between glycogen synthase phosphorylation and subcellular localization have come from studies of rabbit and human muscle. Prats et al. [210] reported that, after glycogen depletion by electrical stimulation, rabbit muscle glycogen synthase dephosphorylated at site 1b and sites 2 + 2a redistributed to specialized spherical structures as a prelude to resynthesis. In a subsequent study of human muscle, further correlation between glycogen synthase phosphorylation and subcellular localization was made [211]. Enzyme phosphorylated at site 1b was mainly associated with intramyofibrillar particles, whereas phosphorylation at site 2 + 2a was associated with intermyofibrillar and subsarcolemmal particles. It was proposed that site 1b phosphorylation was mediated by adrenaline activation of PKA following exercise. This would provide a function for site 1b, which has no direct effect on activity and which is absent from liver glycogen synthase.

Lysosomal disposal of glycogen

Cytosolic degradation of glycogen by phosphorylase and debranching enzyme AGL has commanded much attention, perhaps because it has been such fertile ground for the discovery of biochemical and hormonal mechanisms. However, glycogen is also disposed via a lysosomal pathway, the importance of which is underscored by Pompe disease (glycogen storage disease type II), in which the lysosomal α -glucosidase (GAA) is mutated [74]. Glycogen overaccumulates in lysosomes and vesicular structures [212]. In its most severe form, Pompe disease is fatal within the first year of life, with cardiomyopathy and

muscular hypotonia (OMIM ID #232300). It has been reported that as much as 10% of hepatocyte glycogen is present in the lysosome [28,213]. The exact mechanism by which glycogen is normally transferred to the lysosome is unknown, but is most likely to involve some autophagic or autophagy-like vesicular trafficking (Figure 13). Autophagy comprises a family of processes initially described as a mechanism for random recycling of cellular materials under conditions of nutritional deprivation [214,215]. The type of autophagy that has been most studied, macroautophagy, involves engulfment of cargo within a double membrane to form autophagosomes that ultimately fuse with the lysosome where the cargo is degraded [214–216]. From the intense research activity in this area, it is becoming clear that there are many variants of the basic autophagic process that can have separate controls, specific cargoes and different functions [217,218]. Glycogen has been linked specifically to autophagy. The term ‘glycogen autophagy’ has been applied particularly to the liver of newborns (reviewed in [219]). Glycogen has been reported to accumulate in several organs, notably liver and heart, of the fetus before term, presumably to provide energy reserves for use after the trauma of birth [220]. For the liver, and the newborn in general, the hepatic glycogen reserves are especially important since gluconeogenesis is not well developed at birth [220] and therefore lysosomal degradation of liver glycogen is critically important. Another connection with autophagy is provided by the work of Raben et al. [221] on Pompe disease. From studies of muscle in a mouse model of Pompe disease, *GAA*^{-/-} mice, they have shown that massive overaccumulation of glycogen in lysosomes, characteristic of the disease, was accompanied by a dramatic increase of glycogen-containing autophagosomes and late endosomes, which they referred to as ‘autophagic build-up’ [221]. Subsequently, mice were generated that combined a homozygous null *GAA* mutation with muscle-specific disruption of the genes encoding Atg5 [222] or Atg7 [223], important autophagy proteins. Loss of Atg5 function indeed diminished autophagic build-up in muscle, but made the clinical phenotype worse. Loss of Atg7 had a similar effect and decreased glycogen by 50–60%. Enzyme replacement therapy (delivery of GAA directly to the animals) normalized glycogen levels in the autophagy-deficient mice [223], making selective suppression of autophagy a promising therapeutic approach for Pompe disease patients.

A totally different link between glycogen and autophagy came from analysis of yeast glycogen metabolism where an unbiased genetic screen showed that two prototypical yeast autophagy genes, *ATG1* and *ATG13*, could restore defective glycogen accumulation to a *snf1* mutant strain [224]. In yeast, defective Snf1p, the orthologue of mammalian AMPK catalytic subunit, causes failure to accumulate glycogen. Snf1p was then found to be a positive regulator of autophagy acting upstream of Atg1p; in yeast, transport of glycogen to the vacuole, the approximate equivalent of the mammalian lysosome, actually serves to store glycogen which is only used very late in starvation, possibly for sporulation, when the yeast vacuolar GAA is induced. A genome-wide survey of yeast for genes whose deletion affected glycogen metabolism revealed that the second largest category of genes identified, ~60, were involved in some way in vesicular trafficking or vacuolar function [225]. Subsequent studies of mammalian autophagy showed that AMPK is also a positive regulator of autophagy [226] and, more recently, implicated AMPK as an upstream regulator of ULK1 [227–230], a mammalian orthologue of Atg1p [231]. One might speculate whether activating mutations of the AMPK γ -subunit might be causing excessive autophagy that is associated with the

pathological overaccumulation of glycogen, via mechanisms such as described below. If a downstream trafficking event, for example, the fusion of glycogen-laden autophagosomes with the lysosome, became limiting, there could be a build up of glycogen vesicles such as is seen in PRKAG2 cardiomyopathy or Pompe disease.

Mechanistically, how is glycogen transported to lysosomes? If vesicular transport is involved, one would expect a means to associate glycogen with membranes. Using electron microscopy, glycogen particles are often reported to be close to membranes, endoplasmic reticulum in liver [232] or sarcoplasmic reticulum in muscle [15]. Recently, Stbd1 has emerged as a candidate to anchor glycogen to membrane locations [55]. In independent work, Stbd1 was identified as being associated with liver glycogen in a proteomics study and proposed to be involved in locating glycogen to membrane compartments in cells [45]. Stbd1 has a highly conserved N-terminal 24-residue hydrophobic sequence and a C-terminal CBM20 domain [233], with an intervening sequence predicted to be disordered [55]. *In vitro*, Stbd1 binds to polysaccharides, preferentially interacting with less branched structures such as the amylopectin of plant starch or the glycogen isolated from laforin-knockout mice (see the next section). In MGSKO and LGSKO mice, lacking muscle and liver glycogen respectively, Stbd1 levels are decreased, suggesting a connection between Stbd1 and glycogen metabolism. Expression of Stbd1 in COS cells resulted in the formation of large perinuclear structures, as judged by immunofluorescence, co-localized with glycogen identified by PAS staining [55]. Point mutations in the CBM20 domain designed to disable glycogen binding did not alter Stbd1 perinuclear localization, but eliminated glycogen co-localization. Deletion of the hydrophobic N-terminus of Stbd1 led to a diffuse cytosolic distribution, supporting the idea that it serves to direct Stbd1 to intracellular membranes.

This first effort at assessing the function of Stbd1 provides plausible evidence for a role in glycogen metabolism, with the hypothesis that Stbd1 anchors glycogen to intracellular membranes. Yeast two-hybrid screens using Stbd1 as bait identified Stbd1 itself as an interacting protein, suggesting an oligomeric structure, GABARAP (γ -aminobutyric acid type A receptor-associated protein) and GABARAPL1 (GABARAP-like 1). The last two are members of the mammalian ATG8 family of autophagy proteins [234,235]. Interaction of both GABARAP and GABARAPL1 with Stbd1 was validated by co-expression in COS cells and co-immunoprecipitation. By immunofluorescence, Stbd1 was strongly co-localized with GABARAPL1, less so with GABARAP, in the perinuclear structures described above. Similar co-localization was observed between Stbd1 and endogenous GABARAPL1. The association between Stbd1 and GABARAPL1 provides a tantalizing connection with autophagy. Yeast have a single *ATG8* gene that is thought to be critically involved in the formation of autophagosomes [234]. The emerging sense is that selectivity can be conferred by interaction of Atg8 with specific receptor proteins [217,218]. In mammals, the situation is more complex as there are six orthologues of Atg8, the best studied being LC3 (light chain 3), whose lipidation is often used as a marker for autophagy induced by nutritional stresses [236]. The interaction of ATG8 family members with different cargo-specifying receptors may thus allow for a variety of selective autophagy pathways whose operation need not mimic exactly the traditional macroautophagy process mediated by LC3. Little is known about the function of GABARAPL1 [237]. A current hypothesis, then, is that Stbd1 tethers glycogen to membranes and, by an as yet undefined mechanism involving interaction with

GABARAPL1, participates in the trafficking of glycogen to the lysosome, the process of ‘glycogen autophagy’ or ‘glycophagy’. Since Stbd1 *in vitro* shows a preference for binding to poorly branched and/or highly phosphorylated glycogen, it could favour the disposal of aberrant glycogen particles and be part of a quality-control mechanism. Alternatively, it might be controlled by conditions or stimuli that tend to produce aberrant glycogen. Much remains to be learned about the function of Stbd1 and the phenotype of an Stbd1-knockout mouse, currently under construction, will be of considerable interest.

LAFORA DISEASE AND GLYCOGEN PHOSPHORYLATION

A century ago, Gonzalo Lafora reported autopsy results from patients with teenage-onset myoclonus epilepsy with associated dementia [238]. He observed in ganglion cells ‘amyloid bodies’, a term used at the time to describe material that stained like starch. We now know that these ‘Lafora bodies’ are actually deposits that contain poorly branched insoluble glycogen-like carbohydrate, sometimes called polyglucosan, and are a hallmark of Lafora disease, an autosomal recessive fatal neurodegenerative disorder categorized as a progressive myoclonus epilepsy. Symptoms start in early adolescence and progress as stimulus-sensitive grand mal tonic-clonic, absences, and visual and myoclonic seizures. Rapid progressive dementia develops leading to death typically within 10 years of the first symptom [39–41,239]. Lafora disease is very rare, found most often in parts of the world where consanguinity is common [240]. Lafora bodies are found in many tissues, including the brain, skeletal muscle, heart and liver; their presence in neurons is widely considered causative of the disease. Mutations in two genes, *EPM2A* (epilepsy progressive myoclonus type 2A) and *EPM2B* (epilepsy progressive myoclonus type 2B), account for approximately 90% of Lafora cases [241]. *EPM2A* or *EPM2B* encode the proteins laforin and malin respectively.

Laforin

Minassian et al. [53] identified the laforin gene by positional cloning. Laforin is ubiquitous, with the highest expression levels in skeletal muscle, liver, kidney, heart and brain, tissues with abundant Lafora bodies in Lafora patients [54,242]. Laforin contains the signature DSP (dual-specificity phosphatase) catalytic motif, HCXXGXXRS/T [243], and can dephosphorylate phosphoserine/phosphothreonine, phosphotyrosine [244] and the generic phosphatase substrate PNPP (*p*-nitrophenyl phosphate) *in vitro* [245]. Additionally, laforin contains a CBM20 domain that binds complex carbohydrates including glycogen, amylopectin and polyglucosan [245–247]. Laforin is conserved in all vertebrates and in a small defined group of invertebrates and protists, including *Toxoplasma gondii*, that are of red algal descent, possess a true mitochondrion and produce floridean starch, a complex carbohydrate resembling amylopectin [248,249].

In mammals, laforin has been reported to bind several proteins involved in glycogen metabolism, including glycogen synthase, GSK3, PTG and malin [250–253]. HIRIP5 [HIRA (histone cell cycle regulation defective homologue A)-interacting protein 5], a cytosolic protein involved in iron metabolism [254], *Epm2a*-interacting protein 1, a protein with unknown function [255], the Alzheimer’s disease protein tau [256], and the $\alpha 2$ and $\beta 2$

subunits of AMPK [257] also interact with laforin. Some 59 disease-causing mutations and several polymorphisms in the *EPM2A* gene have been described. Of those tested, almost all affect polysaccharide binding or phosphatase activity (The Lafora Progressive Myoclonus Epilepsy Mutation and Polymorphism Database; <http://projects.tcag.ca/lafora/>). One mutation was described that had no effect on phosphatase activity and polysaccharide-binding activity, but was reported to affect interaction with PTG [251]. Laforin is extremely sensitive to inhibition by polysaccharides, when assayed using PNPP, but 20% of activity remains at saturation [247]. One disease mutation, W32G [258], is located in the conserved carbohydrate-binding domain and the recombinant phosphatase harbouring this mutation eliminates glycogen binding while retaining significant PNPPase activity [245,247]. Therefore impaired glycogen binding by laforin may be sufficient to cause disease. Another link between laforin and glycogen comes from the observation that laforin protein levels correlate with the amount of glycogen in a series of mouse models in which the muscle glycogen content was genetically manipulated [259].

A prominent hypothesis in Lafora research has been that polyglucosan formation results from an imbalance between the activities of glycogen synthase and branching enzyme. There is precedent since polyglucosans accumulate in other glycogen storage diseases. For example, Andersen disease and adult polyglucosan body disease both result from mutations in the *GBE1* gene, encoding the branching enzyme [260]. Impaired branching activity leads predictably to a less branched form of glycogen. In Tarui disease [261], the *PFKM* gene, encoding the muscle form of phosphofructokinase, is mutated. A build-up of glycolytic intermediates in Tarui patients is thought to drive excessive glycogen synthesis through elevation of glucose 6-phosphate, also resulting in polyglucosan formation, the imbalance in this case caused by increased glycogen elongation. In the GSL mice, described earlier, which overexpress hyperactive glycogen synthase in muscle, overaccumulation of glycogen is accompanied by the development of structures reminiscent of Lafora bodies [262,263]. These observations prompted several groups to seek mechanisms whereby laforin could affect glycogen-synthesizing enzymes, more specifically, how laforin might increase glycogen synthase activity. One candidate is the protein kinase GSK3 which contains an inhibitory phosphorylation site ([109], and see above). Two groups proposed that the inhibitory phosphate of GSK3 can be removed by laforin [252,264], thus potentially leading to activation of glycogen synthase to cause the biosynthetic imbalance. Lohi et al. [252] suggested that laforin's role is to detect polyglucosan appearance during glycogen synthesis and to initiate mechanisms to down-regulate glycogen synthase. Several studies, however, argue against GSK3 β being a substrate for laforin [36,37,191,250,265]. Perhaps most convincing is the observation that the GSK3 phosphorylation state is unchanged in three different genetic mouse models of Lafora disease, in which the *Epm2a* gene is disrupted [36,37], dominant-negative laforin is overexpressed [265] or the *Epm2b* gene is disrupted [191]. Measurements of glycogen synthase and branching enzyme AGL activities in these mice also argued against the 'branching imbalance' hypothesis [265].

Recently, from analyses of *Epm2a*^{-/-} mice, Sanz and colleagues suggested that laforin is a more general regulator of insulin-sensitivity and proposed that laforin is a new component of the insulin signalling cascade [266]. They reported that *Epm2a*^{-/-} mice had enhanced glucose disposal, most prominently in the heart, and many insulin-dependent processes were

hyperactivated when compared with commercial C57BL/6 wild-type controls. GSK3 β phosphorylation was increased, but the authors suggest that this is due to increased insulin signalling rather than a direct result of the inability of laforin to dephosphorylate GSK3 β . In contrast, other experiments comparing *Epm2a*^{-/-} mice with wild-type controls with a matched genetic background revealed no differences in glucose- or insulin-tolerance tests or in the insulin signalling pathway (A.A. DePaoli-Roach, D. Segvich, C. Meyer, Y. Rahimi, C.A. Worby, M.S. Gentry and P.J. Roach, unpublished work). A role for laforin in insulin signalling is thus controversial and needs further investigation.

Laforin and autophagy

As discussed above, autophagy or an autophagy-like process is an important mechanism for glycogen disposal. Independent of this function, autophagy appears to be essential for central nervous system function as its inhibition leads to neurodegeneration, behavioural changes and early death in mice [267]. Autophagy is also thought to remove disease-associated cytoplasmic aggregate-prone proteins, which stain positive with anti-ubiquitin antibodies and accumulate in Lafora disease, most prominently in the vicinity of Lafora bodies [268,269]. Consistent with this theme, Aguado et al. [270] reported that laforin activates autophagy by acting upstream of TSC (tuberous sclerosis complex) 2, a tumour suppressor mutated in patients with TSC [271]. Loss of TSC2 leads to activation of mTOR (mammalian target of rapamycin), which, in addition to activating protein synthesis and cell growth, also potently inhibits autophagy [272]. The authors concluded that laforin inhibits mTOR and thus activates autophagy. Therefore, when laforin is disabled, activation of mTOR would inhibit autophagy to cause the disease phenotype. However, the fact that patients with TSC do not develop Lafora bodies argues against laforin acting upstream of TSC2 as a mechanism for the development of Lafora bodies. Likewise, there are no reports of TSC-like tumours in Lafora patients or the Lafora disease mouse models. Laforin may, however, have multiple functions.

Laforin as a glycogen phosphatase

A promising hypothesis in Lafora research was introduced by Dixon and colleagues [250] by demonstrating that laforin dephosphorylates amylopectin, the major component of plant starch. Amylopectin has chemistry comparable with that of glycogen (α -1,4-glycosidic linkages with less frequent α -1,6-branch points) and contains a significant amount of covalent phosphate in the form of C₆- and C₃-phosphomonoesters [273]. Worby et al. [250] also attempted to measure dephosphorylation of commercially available rabbit liver glycogen by laforin, but were unsuccessful, possibly because of the lack of assay sensitivity and/or the low phosphate content of liver glycogen. Tagliabracci et al. [37] were able to demonstrate that laforin could dephosphorylate rabbit muscle glycogen *in vitro*. Muscle glycogen contains approximately 10-fold more phosphate than rabbit liver glycogen [34,35]. Laforin released ~25% of the phosphate present in undigested rabbit muscle glycogen. Digestion of the glycogen with glucosidases in the presence of laforin led to release of 90% of the phosphate, suggesting that the majority of phosphates in the native particle are sterically protected from the phosphatase. Laforin activity towards glycogen is dependent on a functional carbohydrate-binding domain, as W32G mutant laforin was unable to bind and dephosphorylate glycogen, yet still retained significant activity toward PNPP [37]. The

hypothesis that laforin is a physiological glycogen phosphatase was strengthened by analysis of highly purified glycogen from laforin-knockout mice. Glycogen phosphate levels were 4–6-fold higher in the muscle of *Epm2a*^{-/-} mice compared with their wild-type counterparts [36,37]. Furthermore, glycogen from *Epm2a*^{-/-} mice displayed a progressive deterioration in structure and solubility that paralleled the formation of Lafora bodies. Laforin-dependent hydrolysis of the phosphate in glycogen from *Epm2a*^{-/-} mice largely reversed the abnormal appearance of the polysaccharide by electron microscopy [36]. How phosphate disturbs glycogen structure and chemical properties is not fully understood, but a possibility is that phosphate disrupts the elaborate hydrogen-bonding network associated with helical polyglucose [25,26].

Malin

EPM2B (also called *NHLRC1*) encodes malin, a 395-residue protein that contains an N-terminal RING finger domain followed by six NHL domains [274]. Some 56 disease-causing mutations and several polymorphisms in the *EPM2B* gene have been described (The Lafora Progressive Myoclonus Epilepsy Mutation and Polymorphism Database; <http://projects.tcag.ca/lafora/>). The RING finger domain is characteristic of E3 ubiquitin ligases [275] and Gentry et al. [253] reported that malin interacts with laforin and catalyses its polyubiquitylation *in vitro* and in cultured cells resulting in its proteasome-dependent degradation. As noted, laforin protein levels correlate with glycogen in a series of mouse models in which the muscle glycogen content was genetically manipulated. Thus, the increased laforin levels in patients carrying malin mutations [276] as well as *Epm2b* knockout mice [191] may be a consequence of over-accumulation of glycogen. In any event, if the physiological function of malin is to mediate the destruction of laforin, it is hard to reconcile the fact that Lafora disease is caused by recessive mutations in either the *EPM2A* or *EPM2B* genes. On the basis of the model of Gentry et al. [253], defective malin would up-regulate laforin protein levels.

Recent studies, mainly using cell culture systems, have reported that several proteins involved in glycogen metabolism are substrates for malin, including glycogen synthase, the PP1 glycogen-targeting subunit PTG, the debranching enzyme AGL and AMPK [277–280]. Two independent laboratories have reported that co-expression of malin and laforin resulted in the ubiquitylation and proteasome-dependent degradation of PTG [277,278]. They proposed that laforin, via its glycogen-binding domain, could recruit malin to the glycogen particle to promote the degradation of PTG and glycogen synthase, thereby inhibiting glycogen synthesis. They also suggest that neurons contain the enzymatic machinery for synthesizing glycogen, but do not do so because glycogen synthase is in an inactivated hyperphosphorylated form. Loss of laforin or malin would inhibit malin-mediated degradation of PTG and glycogen synthase, driving excessive glycogen accumulation by dephosphorylation of glycogen synthase. Interestingly, co-expression of the catalytically inactive form of laforin had the same effect on the degradation of PTG. However, patients with mutations in laforin that abolish phosphatase activity still develop Lafora bodies and the neurological sequelae. Perhaps the phosphatase domain is required for an independent, but interrelated, function. Cheng et al. [279] identified the debranching enzyme AGL as a substrate for malin-mediated ubiquitylation and proteasome-dependent degradation. This

ubiquitylation event, unlike the ones discussed above, was independent of laforin. The authors proposed that mutations in malin would prevent the ubiquitylation and proteasome-dependent degradation of AGL, resulting in increased AGL protein, removal of α -1,6-glycosidic linkages and hence polyglucosan formation. However, on the basis of the two-stage degradation of glycogen by phosphorylase and debranching enzyme AGL, excessive AGL activity should only reduce branching frequency if phosphorylase, normally an abundant enzyme, becomes limiting. Other reports [257,281] have proposed that AMPK phosphorylates laforin, enhances its association with malin and thereby regulates laforin and malin targets. AMPK was also reported to phosphorylate the PTG phosphatase subunit and target it for degradation by the malin–laforin complex [282]. However, DePaoli-Roach et al. [191] showed that physiological activation of AMPK in muscle by exercising mice did not alter the levels of PTG, AGL, laforin or glycogen synthase, arguing against AMPK-mediated degradation of these proteins, at least on this time scale. In addition, there is a report that malin catalyses Lys⁶³ ubiquitylation of the AMPK β -subunit when it is part of a trimeric complex in cells, a modification that would not target degradation [280]. Other studies have suggested that laforin and malin are recruited to aggresomes upon proteasomal inhibition [283]. The authors proposed that the centrosomal accumulation of malin and laforin enhances the ubiquitylation of malin substrates, facilitating their efficient degradation by the proteasome. In addition, laforin and malin were shown to form a functional complex with HSP70 (heat-shock protein 70) to suppress the cellular toxicity of misfolded proteins by promoting their degradation through the unfolded protein response [284].

Analysis of *Epm2b*^{-/-} mice challenges a number of the proposed mechanisms of action of malin, since one would expect that loss of the E3 ubiquitin ligase would result in increased protein levels of the physiological substrates [191]. At 3 months of age, AGL and PTG levels were unchanged, as was the glycogen synthase activity ratio, arguing against AGL and PTG being substrates for malin-mediated degradation. Laforin protein, however, was significantly increased, especially in brain, and was redistributed from a soluble to an insoluble fraction [191]. This finding could be consistent with laforin being a malin target. The other interpretation is that increased insoluble glycogen sequesters the laforin, protecting it from degradation. Extensive analysis of glycogen-metabolizing enzymes in these mice failed to reveal any significant alterations, despite the fact that Lafora bodies were present in neurons, skeletal muscle and heart. Turnbull et al. [285] reported a 1.5-fold increase in skeletal muscle and liver glycogen phosphate levels in 6-month-old mice from an independently generated *Epm2b*^{-/-} mouse model. These results suggest that malin regulates laforin activity and/or distribution, leading to the hyperphosphorylation of glycogen and subsequent formation of polyglucosan seen in Lafora patients.

Lafora bodies and Lafora disease

There has been some debate as to whether Lafora bodies are the cause or the consequence of Lafora disease [240]. One argument stems from the observation that laforin-knockout mice, at least in one study, develop neuronal degeneration before Lafora body formation, both of which precede behavioural dysfunctions [286]. However, the recent generation of a double-knockout mouse model lacking both laforin and PTG makes a strong case that glycogen, and Lafora bodies in particular, is linked to the neuropathology [287]. *Ppp1r3c*^{-/-} mice have a

30% reduction in muscle glycogen, correlated with decreased glycogen synthase activation state and no change in phosphorylase [155]. Brain glycogen is reduced by 75%. As noted above, in older *Epm2a*^{-/-} mice, glycogen overaccumulates. In the study of Turnbull et al. [287], total glycogen was elevated 4–5-fold in brain and muscle of 12-month-old *Epm2a*^{-/-} mice. This correlated with massive increases in the number of Lafora bodies observed histochemically and with severe neurological symptoms. In the *Epm2a*^{-/-} *Ppp1r3c*^{-/-} double-knockout mice, glycogen and Lafora body abundance were dramatically decreased and the neurological defects of *Epm2a*^{-/-} mice were resolved. Very recently, the presence of a genetic variant of PTG that decreased glycogen levels was associated with a slower progression of Lafora disease [288]. By epistasis, laforin is therefore upstream of PTG with regard to Lafora body formation. The simplest explanation is that reduced capacity to synthesize glycogen due to defects in PTG is sufficient to suppress polyglucosan formation. However, other roles for PTG cannot be excluded.

Current status of Lafora research

The molecular era of Lafora research began in 1998. In only a dozen years or so, a vibrant research enterprise has emerged around what is a very rare disease. The primary focus of most work has been to understand the functions of the products of the two major causative genes, laforin and malin, and how their impairment could explain the disease process. The results in this young research area, as one might expect, provide numerous hypotheses (Figure 14), some inconsistent results and much healthy debate. The study of the *Epm2a*^{-/-} *Ppp1r3c*^{-/-} mice would appear to make a strong case that Lafora disease is indeed a glycogen storage disease [287]. The evidence in our view supports the idea that laforin evolved as an *in vivo* glycogen phosphatase, removing C₂- and C₃-phosphomonoesters from glycogen, and associating with glycogen via its CBM20 domain. The properties of hyperphosphorylated glycogen in *Epm2a*^{-/-} mice match the reduced solubility of polyglucosans. Considering also the observation of increased glycogen phosphorylation in *Epm2b*^{-/-} mice, we propose that glycogen phosphorylation is a central causative factor in Lafora disease and that laforin functions in a repair or damage-control mechanism, to remove the rare phosphate introduced into glycogen by glycogen synthase. Such a function for laforin can also explain why the onset of symptoms in Lafora patients is not immediately at birth. Even without functional laforin, glycogen particles can undergo normal cycles of degradation and resynthesis, and it is not until the phosphate exceeds a threshold that the glycogen structure in some particles is disturbed and destined to become a Lafora body. Unresolved is whether laforin has other substrates or functions *in vivo*. Besides the obvious genetic link between laforin and malin, direct physical interaction between the two proteins has been suggested by several studies so that defects in laforin might also have an impact on malin function. This may help to explain some of the other roles proposed for laforin.

What is the status of the imbalance theory? In young *Epm2a*^{-/-} mice, there are no great changes in glycogen synthase and branching enzyme [36,265]. In old *Epm2a*^{-/-} mice, there is a hyperaccumulation of glycogen synthase, sequestered with polyglucosan, but its activity is not correspondingly increased. Therefore there is little supporting evidence for the theory at this time. What is definitely unclear is the relationship between glycogen phosphorylation and its acquisition of a sparsely branched structure. In the absence of laforin, does

phosphorylation precede the diminished branching or do they both progress simultaneously? Is there any mechanistic relationship, with phosphate blocking branching enzyme action or being a normal part of the branching process, for example? Is there an unappreciated control of branching enzyme?

Perhaps the biggest unknown is the function of malin. As noted, there is no shortage of proposed targets (Figure 14), based mainly on experiments with cells. The levels of several of these protein targets are unchanged in tissue from *Epm2b*^{-/-} mice making it hard to reconcile with the idea that the E3 ubiquitin ligase activity of malin targets these proteins for degradation. Perhaps the ubiquitylation has a different role. Perhaps the physiologically critical target for malin has yet to be discovered. Or, like laforin, perhaps malin has functions not obvious from its primary structure. An area that will probably receive more attention in the future is the possible connection between Lafora disease and autophagy, whether generalized macroautophagy or a more specialized process specific to glycogen, i.e. glycophagy. If lysosomal disposal is a means to eliminate damaged glycogen, for example excessively phosphorylated glycogen, malin or a malin–laforin complex might play a role in that process.

CONCLUSIONS

After 150 years, one might have imagined that there would not be much more to learn about glycogen and its metabolism. Indeed, we now know much about the biochemistry, molecular biology and genetics, we have considerable molecular insight into the structure and mechanisms of the metabolic enzymes, and we have gained significant understanding of the control of glycogen metabolism in relation to nutritional status. Knowledge of the signalling pathways is still incomplete, however, especially with regard to muscle contraction and the role of AMPK. And there have been some unexpected new findings. The introduction of phosphate into glycogen as an error in glycogen synthase action underlies a possible link to Lafora disease, and leads to discussion of a totally new aspect of glycogen metabolism, namely that of its covalent phosphate and the role of the laforin phosphatase. The function of the other Lafora disease gene, which encodes malin, is a major unresolved question. Lysosomal disposal of glycogen, long recognized in relation to Pompe disease, is now being revisited to elucidate the molecular mechanism of the transport of glycogen to lysosomes. Other spatial aspects of glycogen metabolism, again first described many years ago, are beginning to be examined with modern methods for imaging subcellular localizations. The glycogen particle may be a prime example of a metabolic machine, accepting substrates and releasing products in response to signals from the cell, but still functioning autonomously wherever it is built.

Acknowledgments

FUNDING

Our research is supported by the National Institutes of Health [grant numbers R37 DK027221, R01 NS056454, R01 DK079887 and R21 HL108301].

Abbreviations

AGL	amylo- α -1,6-glucosidase, 4- α -glucanotransferase
AICAR	5-amino-4-imidazolecarboxamide riboside
AMPK	AMP-activated protein kinase
CBM20	carbohydrate-binding module 20
GAA	acid α -glucosidase
GABARAP	γ -aminobutyric acid type A receptor-associated protein
GABARAPLG	GABARAP-like 1
GKRP	glucokinase regulatory protein
GLUT	glucose transporter
GSK3	glycogen synthase kinase 3
LC3	light chain 3
LGSKO	liver-specific glycogen synthase-knockout
MCA	Metabolic Control Analysis
MGSKO	muscle-specific glycogen synthase-knockout
mTOR	mammalian target of rapamycin
PAS	periodic acid–Schiff
PKA	protein kinase A
PKB	protein kinase B
PNPP	<i>p</i> -nitrophenyl phosphate
PP	protein phosphatase
PRKAG2	AMPK γ 2 non-catalytic subunit
PSSM	polysaccharide storage myopathy
PTG	protein targeting to glycogen
Stbd1	starch-binding domain protein 1
TCA	trichloroacetic acid
TSC	tuberous sclerosis complex
UGPPase	UDP-glucose pyrophosphatase

References

1. Preiss, J.; Walsh, DA. The comparative biochemistry of glycogen and starch. In: Ginsburg, V.; Robbins, P., editors. *Biology of Carbohydrates*. John Wiley and Sons; New York: 1981. p. 199-314.
2. Ball S, Guan HP, James M, Myers A, Keeling P, Mouille G, Buleon A, Colonna P, Preiss J. From glycogen to amylopectin: a model for the biogenesis of the plant starch granule. *Cell*. 1996; 86:349–352. [PubMed: 8756717]
3. Zeeman SC, Smith SM, Smith AM. The diurnal metabolism of leaf starch. *Biochem J*. 2007; 401:13–28. [PubMed: 17150041]
4. Young FG. Claude Bernard and the discovery of glycogen: a century of retrospect. *Br Med J*. 1957; 1:1431–1437. [PubMed: 13436813]
5. Stalmans W, Bollen M, Mvumbi L. Control of glycogen synthesis in health and disease. *Diabetes Metab Rev*. 1987; 3:127–161. [PubMed: 3032540]
6. Gannon MC, Nuttall FQ. Glycogen in liver: characteristics and biosynthesis. *Trends Glycosci Glycotechnol*. 1996; 8:163–194.
7. Villar-Palasi C, Guinovart JJ. The role of glucose 6-phosphate in the control of glycogen synthase. *FASEB J*. 1997; 11:544–558. [PubMed: 9212078]
8. Bollen M, Keppens S, Stalmans W. Specific features of glycogen metabolism in the liver. *Biochem J*. 1998; 336:19–31. [PubMed: 9806880]
9. Roach PJ, Cheng C, Huang D, Lin A, Mu J, Skurat AV, Wilson W, Zhai L. Novel aspects of the regulation of glycogen storage. *J Basic Clin Physiol Pharmacol*. 1998; 9:139–151. [PubMed: 10212831]
10. Roach, PJ. Biosynthesis of glycogen. In: Ernst, B.; Sinay, P.; Hart, G., editors. *Oligosaccharides in Chemistry and Biology: a Comprehensive Handbook*. John Wiley and Sons; New York: 2000. p. 349-361.
11. Roach, P.J.; Skurat, AV.; Harris, RA. Regulation of glycogen metabolism. In: Jefferson, L.S.; Cherrington, A.D., editors. *Handbook of Physiology Section 7: The Endocrine System volume II. The Endocrine Pancreas and Regulation of Metabolism*. Oxford University Press; Oxford: 2001. p. 609-647.
12. Roach PJ. Glycogen and its metabolism. *Curr Mol Med*. 2002; 2:101–120. [PubMed: 11949930]
13. Shearer J, Graham TE. New perspectives on the storage and organization of muscle glycogen. *Can J Appl Physiol*. 2002; 27:179–203. [PubMed: 12179957]
14. Ferrer JC, Favre C, Gomis RR, Fernández-Novell JM, García-Rocha M, de la Iglesia N, Cid E, Guinovart JJ. Control of glycogen deposition. *FEBS Lett*. 2003; 546:127–132. [PubMed: 12829248]
15. Shearer J, Graham TE. Novel aspects of skeletal muscle glycogen and its regulation during rest and exercise. *Exercise Sport Sci Rev*. 2004; 32:120–126.
16. Greenberg CC, Jurczak MJ, Danos AM, Brady MJ. Glycogen branches out: new perspectives on the role of glycogen metabolism in the integration of metabolic pathways. *Am J Physiol Endocrinol Metab*. 2006; 291:E1–E8. [PubMed: 16478770]
17. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. *Biochem J*. 2008; 414:1–18. [PubMed: 18651836]
18. Graham TE. Glycogen: an overview of possible regulatory roles of the proteins associated with the granule. *Appl Physiol Nutr Metab*. 2009; 34:488–492. [PubMed: 19448719]
19. Graham TE, Yuan Z, Hill AK, Wilson RJ. The regulation of muscle glycogen: the granule and its proteins. *Acta Physiol*. 2010; 199:489–498.
20. Markan KR, Jurczak MJ, Brady MJ. Stranger in a strange land: roles of glycogen turnover in adipose tissue metabolism. *Mol Cell Endocrinol*. 2010; 318:54–60. [PubMed: 19703517]
21. Wilson WA, Roach PJ, Montero M, Baroja-Fernández E, Muñoz FJ, Eydallin G, Viale AM, Pozueta-Romero J. Regulation of glycogen metabolism in yeast and bacteria. *FEMS Microbiol Rev*. 2010; 34:952–985. [PubMed: 20412306]
22. Gunja-Smith Z, Marshall JJ, Mercier C, Smith EE, Whelan WJ. A revision of the Meyer–Bernfeld model of glycogen and amylopectin. *FEBS Lett*. 1970; 12:101–104. [PubMed: 11945551]

23. Melendez-Hevia E, Waddell TG, Shelton ED. Optimization of molecular design in the evolution of metabolism: the glycogen molecule. *Biochem J.* 1993; 295:477–483. [PubMed: 8240246]
24. Meléndez R, Meléndez-Hevia E, Cascante M. How did glycogen structure evolve to satisfy the requirement for rapid mobilization of glucose? A problem of physical constraints in structure building. *J Mol Evol.* 1997; 45:446–455. [PubMed: 9321423]
25. Goldsmith E, Sprang S, Fletterick R. Structure of maltoheptaose by difference Fourier methods and a model for glycogen. *J Mol Biol.* 1982; 156:411–427. [PubMed: 7086906]
26. Gessler K, Uson I, Takaha T, Krauss N, Smith SM, Okada S, Sheldrick GM, Saenger W. V-Amylose at atomic resolution: X-ray structure of a cycloamylose with 26 glucose residues (cyclomaltohexacosaoase). *Proc Natl Acad Sci USA.* 1999; 96:4246–4251. [PubMed: 10200247]
27. Drochmans P. Morphologie du glycogène: étude du microscope électronique de colorations négative du glycogène particulaire. *J Ultrastruct Res.* 1962; 6:141–163.
28. Geddes R, Harvey JD, Wills PR. The molecular size and shape of liver glycogen. *Biochem J.* 1977; 163:201–209. [PubMed: 869923]
29. Sullivan MA, Vilaplana F, Cave RA, Stapleton D, Gray-Weale AA, Gilbert RG. Nature of α and β particles in glycogen using molecular size distributions. *Biomacromolecules.* 2010; 11:1094–1100. [PubMed: 20196533]
30. Konkolewicz D, Gilbert RG, Gray-Weale A. Randomly hyperbranched polymers. *Phys Rev Lett.* 2007; 98:238301. [PubMed: 17677941]
31. Kirkman BR, Whelan WJ, Bailey JM. The distribution of glucosamine in mammalian glycogen from different species, organs and tissues. *Biofactors.* 1989; 2:123–126. [PubMed: 2624672]
32. Kirkman BR, Whelan WJ. Glucosamine is a normal component of liver glycogen. *FEBS Lett.* 1986; 194:6–11. [PubMed: 3079709]
33. Fontana JD. The presence of phosphate in glycogen. *FEBS Lett.* 1980; 109:85–92. [PubMed: 6153366]
34. Lomako J, Lomako WM, Kirkman BR, Whelan WJ. The role of phosphate in muscle glycogen. *Biofactors.* 1994; 4:167–171. [PubMed: 7916962]
35. Lomako J, Lomako WM, Whelan WJ, Marchase RB. Glycogen contains phosphodiester groups that can be introduced by UDPglucose: glycogen glucose 1-phosphotransferase. *FEBS Lett.* 1993; 329:263–267. [PubMed: 8396041]
36. Tagliabracci VS, Girard JM, Segvich D, Meyer C, Turnbull J, Zhao X, Minassian BA, Depaoli-Roach AA, Roach PJ. Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. *J Biol Chem.* 2008; 283:33816–33825. [PubMed: 18852261]
37. Tagliabracci VS, Turnbull J, Wang W, Girard JM, Zhao X, Skurat AV, Delgado-Escueta AV, Minassian BA, Depaoli-Roach AA, Roach PJ. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen *in vivo*. *Proc Natl Acad Sci USA.* 2007; 104:19262–19266. [PubMed: 18040046]
38. Tagliabracci VS, Heiss C, Karthik C, Contreras CJ, Glushka J, Ishihara M, Azadi P, Hurley TD, DePaoli-Roach AA, Roach PJ. Phosphate incorporation during glycogen synthesis and Lafora disease. *Cell Metab.* 2011; 13:274–282. [PubMed: 21356517]
39. Gentry MS, Dixon JE, Worby CA. Lafora disease: insights into neurodegeneration from plant metabolism. *Trends Biochem Sci.* 2009; 34:628–639. [PubMed: 19818631]
40. Delgado-Escueta AV. Advances in Lafora progressive myoclonus epilepsy. *Curr Neurol Neurosci Rep.* 2007; 7:428–433. [PubMed: 17764634]
41. Andrade DM, Turnbull J, Minassian BA. Lafora disease, seizures and sugars. *Acta Myol.* 2007; 26:83–86. [PubMed: 17915579]
42. Cavanagh JB. Corpora amylacea and the family of polyglucosan diseases. *Brain Res Rev.* 1999; 29:265–295. [PubMed: 10209236]
43. Rosai J, Lascano EF. Basophilic (mauicoid) degeneration of myocardium: a disorder of glycogen metabolism. *Am J Pathol.* 1970; 61:99–116. [PubMed: 4099034]
44. Rybicka KK. Glycosomes: the organelles of glycogen metabolism. *Tissue Cell.* 1996; 28:253–265. [PubMed: 8701432]

45. Stapleton D, Nelson C, Parsawar K, McClain D, Gilbert-Wilson R, Barker E, Rudd B, Brown K, Hendrix W, O'Donnell P, Parker G. Analysis of hepatic glycogen-associated proteins. *Proteomics*. 2010; 10:2320–2329. [PubMed: 20391537]
46. Meyer F, Heilmeyer LM Jr, Haschke RH, Fischer EH. Control of phosphorylase activity in a muscle glycogen particle. I. Isolation and characterization of the protein–glycogen complex. *J Biol Chem*. 1970; 245:6642–6648. [PubMed: 4320610]
47. Heilmeyer LM Jr, Meyer F, Haschke RH, Fischer EH. Control of phosphorylase activity in a muscle glycogen particle. II. Activation by calcium. *J Biol Chem*. 1970; 245:6649–6656. [PubMed: 4320611]
48. Haschke RH, Heilmeyer LM Jr, Meyer F, Fischer EH. Control of phosphorylase activity in a muscle glycogen particle. III. Regulation of phosphorylase phosphatase. *J Biol Chem*. 1970; 245:6657–6663. [PubMed: 4320612]
49. Machovic M, Janecek S. The evolution of putative starch-binding domains. *FEBS Lett*. 2006; 580:6349–6356. [PubMed: 17084392]
50. Christiansen C, Abou Hachem M, Janecek S, Vikso-Nielsen A, Blennow A, Svensson B. The carbohydrate-binding module family 20: diversity, structure, and function. *FEBS J*. 2009; 276:5006–5029. [PubMed: 19682075]
51. Hudson ER, Pan DA, James J, Lucocq JM, Hawley SA, Green KA, Baba O, Terashima T, Hardie DG. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. *Curr Biol*. 2003; 13:861–866. [PubMed: 12747836]
52. Polekhina G, Gupta A, Michell BJ, van Denderen B, Murthy S, Feil SC, Jennings IG, Campbell DJ, Witters LA, Parker MW, et al. AMPK β subunit targets metabolic stress sensing to glycogen. *Curr Biol*. 2003; 13:867–871. [PubMed: 12747837]
53. Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, Dunham I, Gardner R, Fong CY, Carpenter S, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. *Nat Genet*. 1998; 20:171–174. [PubMed: 9771710]
54. Ganesh S, Amano K, Delgado-Escueta AV, Yamakawa K. Isolation and characterization of mouse homologue for the human epilepsy gene, *EPM2A*. *Biochem Biophys Res Commun*. 1999; 257:24–28. [PubMed: 10092504]
55. Jiang S, Heller B, Tagliabracci VS, Zhai L, Irimia JM, DePaoli-Roach AA, Wells CD, Skurat AV, Roach PJ. Starch binding domain-containing protein 1/genethonin 1 is a novel participant in glycogen metabolism. *J Biol Chem*. 2010; 285:34960–34971. [PubMed: 20810658]
56. Caudwell FB, Cohen P. Purification and subunit structure of glycogen-branching enzyme from rabbit skeletal muscle. *Eur J Biochem*. 1980; 109:391–394. [PubMed: 6447599]
57. Marchand I, Chorneyko M, Tarnopolsky M, Hamilton S, Shearer J, Potvin J, Graham TE. Quantification of subcellular glycogen in resting human muscle: granule size, number, and location. *J Appl Physiol*. 2002; 93:1598–1607. [PubMed: 12381743]
58. Lomako J, Lomako WM, Whelan WJ, Dombro RS, Neary JT, Norenberg MD. Glycogen synthesis in the astrocyte: from glycogenin to proglycogen to glycogen. *FASEB J*. 1993; 7:1386–1393. [PubMed: 8224611]
59. Lomako J, Lomako WM, Whelan WJ. Proglycogen: a low-molecular-weight form of muscle glycogen. *FEBS Lett*. 1991; 279:223–228. [PubMed: 1705897]
60. Lomako J, Lomako WM, Whelan WJ. Glycogen metabolism in quail embryo muscle: the role of the glycogenin primer and the intermediate proglycogen. *Eur J Biochem*. 1995; 234:343–349. [PubMed: 8529663]
61. Skurat AV, Lim SS, Roach PJ. Glycogen biogenesis in rat 1 fibroblasts expressing rabbit muscle glycogenin. *Eur J Biochem*. 1997; 245:147–155. [PubMed: 9128736]
62. James AP, Barnes PD, Palmer TN, Fournier PA. Proglycogen and macroglycogen: artifacts of glycogen extraction? *Metab, Clin Exp*. 2008; 57:535–543. [PubMed: 18328357]
63. Katz A. Glycogenin, proglycogen, and glycogen biogenesis: what's the story? *Am J Physiol Endocrinol Metab*. 2006; 290:E757–E758. [PubMed: 16533952]
64. Pederson BA, Chen H, Schroeder JM, Shou W, DePaoli-Roach AA, Roach PJ. Abnormal cardiac development in the absence of heart glycogen. *Mol Cell Biol*. 2004; 24:7179–7187. [PubMed: 15282316]

65. Shearer J, Wilson RJ, Battram DS, Richter EA, Robinson DL, Bakovic M, Graham TE. Increases in glycogenin and glycogenin mRNA accompany glycogen resynthesis in human skeletal muscle. *Am J Physiol Endocrinol Metab.* 2005; 289:E508–E514. [PubMed: 15870102]
66. McGarry JD, Kuwajima M, Newgard CB, Foster DW, Katz J. From dietary glucose to liver glycogen: the full circle round. *Annu Rev Nutr.* 1987; 7:51–73. [PubMed: 3038155]
67. Thorens B, Mueckler M. Glucose transporters in the 21st Century. *Am J Physiol Endocrinol Metab.* 2010; 298:E141–E145. [PubMed: 20009031]
68. Krisman CR, Barengo R. A precursor of glycogen biosynthesis: α -1,4-glucan-protein. *Eur J Biochem.* 1975; 52:117–123. [PubMed: 809265]
69. Kennedy, LD.; Kirkman, BR.; Lomako, J.; Rodriguez, IR.; Whelan, WJ. The biogenesis of rabbit muscle glycogen. In: Berman, MC.; Gevers, W.; Opie, LH., editors. *Membranes and Muscle.* ICSU Press/IRL Press; Oxford: 1985. p. 65-84.
70. Pitcher J, Smythe C, Campbell DG, Cohen P. Identification of the 38-kDa subunit of rabbit skeletal muscle glycogen synthase as glycogenin. *Eur J Biochem.* 1987; 169:497–502. [PubMed: 3121316]
71. Lomako J, Lomako WM, Whelan WJ. A self-glucosylating protein is the primer for rabbit muscle glycogen biosynthesis. *FASEB J.* 1988; 2:3097–3103. [PubMed: 2973423]
72. Yagi T, Baroja-Fernández E, Yamamoto R, Muñoz FJ, Akazawa T, Hong KS, Pozueta-Romero J. Cloning, expression and characterization of a mammalian Nudix hydrolase-like enzyme that cleaves the pyrophosphate bond of UDP-glucose. *Biochem J.* 2003; 370:409–415. [PubMed: 12429023]
73. Heyen CA, Tagliabracci VS, Zhai L, Roach PJ. Characterization of mouse UDP-glucose pyrophosphatase, a Nudix hydrolase encoded by the *Nudt14* gene. *Biochem Biophys Res Commun.* 2009; 390:1414–1418. [PubMed: 19896456]
74. Hirschhorn, R.; Reuser, AJ. Glycogen storage disease type II: acid α -glucosidase (acid maltase) deficiency. In: Scriver, CR.; Beaudet, AL.; Sly, WS.; Valle, D., editors. *The Metabolic and Molecular Basis of Inherited Disease.* McGraw-Hill; New York: 2000. p. 3389-3420.
75. Roach PJ, Skurat AV. Self-glucosylating initiator proteins and their role in glycogen biosynthesis. *Prog Nucleic Acid Res Mol Biol.* 1997; 57:289–316. [PubMed: 9175437]
76. Alonso MD, Lomako J, Lomako WM, Whelan WJ. A new look at the biogenesis of glycogen. *FASEB J.* 1995; 9:1126–1137. [PubMed: 7672505]
77. Lomako J, Lomako WM, Whelan WJ. Glycogenin: the primer for mammalian and yeast glycogen synthesis. *Biochim Biophys Acta.* 2004; 1673:45–55. [PubMed: 15238248]
78. Smythe C, Cohen P. The discovery of glycogenin and the priming mechanism for glycogen biogenesis. *Eur J Biochem.* 1991; 200:625–631. [PubMed: 1915338]
79. Henrissat B, Davies GJ. Glycoside hydrolases and glycosyltransferases: families, modules, and implications for genomics. *Plant Physiol.* 2000; 124:1515–1519. [PubMed: 11115868]
80. Campbell JA, Davies GJ, Bulone V, Henrissat B. A classification of nucleotide-diphospho-sugar glycosyltransferases based on amino acid sequence similarities. *Biochem J.* 1997; 326:929–939. [PubMed: 9334165]
81. Mu J, Skurat AV, Roach PJ. Glycogenin-2, a novel self-glucosylating protein involved in liver glycogen biosynthesis. *J Biol Chem.* 1997; 272:27589–27597. [PubMed: 9346895]
82. Moslemi AR, Lindberg C, Nilsson J, Tajsharghi H, Andersson B, Oldfors A. Glycogenin-1 deficiency and inactivated priming of glycogen synthesis. *N Engl J Med.* 2010; 362:1203–1210. [PubMed: 20357282]
83. Gibbons BJ, Roach PJ, Hurley TD. Crystal structure of the autocatalytic initiator of glycogen biosynthesis, glycogenin. *J Mol Biol.* 2002; 319:463–477. [PubMed: 12051921]
84. Hurley TD, Stout S, Miner E, Zhou J, Roach PJ. Requirements for catalysis in mammalian glycogenin. *J Biol Chem.* 2005; 280:23892–23899. [PubMed: 15849187]
85. Lairson LL, Henrissat B, Davies GJ, Withers SG. Glycosyltransferases: structures, functions, and mechanisms. *Annu Rev Biochem.* 2008; 77:521–555. [PubMed: 18518825]
86. Cao Y, Mahrenholz AM, DePaoli-Roach AA, Roach PJ. Characterization of rabbit skeletal muscle glycogenin: tyrosine 194 is essential for function. *J Biol Chem.* 1993; 268:14687–14693. [PubMed: 8325847]

87. Hurley TD, Walls C, Bennett JR, Roach PJ, Wang M. Direct detection of glycogenin reaction products during glycogen initiation. *Biochem Biophys Res Commun.* 2006; 348:374–378. [PubMed: 16889748]
88. Skurat AV, Dietrich AD, Roach PJ. Interaction between glycogenin and glycogen synthase. *Arch Biochem Biophys.* 2006; 456:93–97. [PubMed: 17055998]
89. Roach PJ, Lerner J. Covalent phosphorylation in the regulation of glycogen synthase activity. *Mol Cell Biochem.* 1977; 15:179–200. [PubMed: 196178]
90. Guinovart JJ, Salavert A, Massague J, Ciudad CJ, Salsas E, Itarte E. Glycogen synthase: a new activity ratio assay expressing a high sensitivity to the phosphorylation state. *FEBS Lett.* 1979; 106:284–288. [PubMed: 115716]
91. Browner MF, Nakano K, Bang AG, Fletterick RJ. Human muscle glycogen synthase cDNA sequence: a negatively charged protein with an asymmetric charge distribution. *Proc Natl Acad Sci USA.* 1989; 86:1443–1447. [PubMed: 2493642]
92. Nuttall FQ, Gannon MC, Bai G, Lee EY. Primary structure of human liver glycogen synthase deduced by cDNA cloning. *Arch Biochem Biophys.* 1994; 311:443–449. [PubMed: 8203908]
93. Farkas I, Hardy TA, Goebel MG, Roach PJ. Two glycogen synthase isoforms in *Saccharomyces cerevisiae* are coded by distinct genes that are differentially controlled. *J Biol Chem.* 1991; 266:15602–15607. [PubMed: 1908457]
94. Smith CH, Brown NE, Lerner J. Molecular characteristics of the totally dependent and independent forms of glycogen synthase from rabbit muscle. II. Some chemical characteristics of the enzyme protein and of its change on interconversion. *Biochim Biophys Acta.* 1971; 242:81–88. [PubMed: 5121616]
95. Skurat AV, Wang Y, Roach PJ. Rabbit skeletal muscle glycogen synthase expressed in COS cells: identification of regulatory phosphorylation sites. *J Biol Chem.* 1994; 269:25534–25542. [PubMed: 7929255]
96. Skurat AV, Roach PJ. Phosphorylation of sites 3a and 3b (Ser⁶⁴⁰ and Ser⁶⁴⁴) in the control of rabbit muscle glycogen synthase. *J Biol Chem.* 1995; 270:12491–12497. [PubMed: 7759494]
97. Ros S, García-Rocha M, Domínguez J, Ferrer JC, Guinovart JJ. Control of liver glycogen synthase activity and intracellular distribution by phosphorylation. *J Biol Chem.* 2009; 284:6370–6378. [PubMed: 19124463]
98. Hardy TA, Roach PJ. Control of yeast glycogen synthase-2 by COOH-terminal phosphorylation. *J Biol Chem.* 1993; 268:23799–23805. [PubMed: 8226915]
99. Huang D, Moffat J, Wilson WA, Moore L, Cheng C, Roach PJ, Andrews B. Cyclin partners determine Pho85 protein kinase substrate specificity *in vitro* and *in vivo*: control of glycogen biosynthesis by Pcl8 and Pcl10. *Mol Cell Biol.* 1998; 18:3289–3299. [PubMed: 9584169]
100. Roach PJ. Control of glycogen synthase by hierarchal protein phosphorylation. *FASEB J.* 1990; 4:2961–2968. [PubMed: 2168324]
101. Roach PJ. Multisite and hierarchal protein phosphorylation. *J Biol Chem.* 1991; 266:14139–14142. [PubMed: 1650349]
102. Zhang W, DePaoli-Roach AA, Roach PJ. Mechanisms of multisite phosphorylation and inactivation of rabbit muscle glycogen synthase. *Arch Biochem Biophys.* 1993; 304:219–225. [PubMed: 8391782]
103. Fiol CJ, Mahrenholz AM, Wang Y, Roeske RW, Roach PJ. Formation of protein kinase recognition sites by covalent modification of the substrate: molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. *J Biol Chem.* 1987; 262:14042–14048. [PubMed: 2820993]
104. ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3 β reveals a primed phosphorylation mechanism. *Nat Struct Biol.* 2001; 8:593–596. [PubMed: 11427888]
105. Bax B, Carter PS, Lewis C, Guy AR, Bridges A, Tanner R, Pettman G, Mannix C, Culbert AA, Brown MJ, et al. The structure of phosphorylated GSK-3 β complexed with a peptide, FRATtide, that inhibits β -catenin phosphorylation. *Structure.* 2001; 9:1143–1152. [PubMed: 11738041]
106. Woodgett JR. Judging a protein by more than its name: GSK-3. *Sci STKE.* 2001; 2001:re12. [PubMed: 11579232]

107. MacAulay K, Doble BW, Patel S, Hansotia T, Sinclair EM, Drucker DJ, Nagy A, Woodgett JR. Glycogen synthase kinase 3 α -specific regulation of murine hepatic glycogen metabolism. *Cell Metab.* 2007; 6:329–337. [PubMed: 17908561]
108. Patel S, Doble BW, MacAulay K, Sinclair EM, Drucker DJ, Woodgett JR. Tissue-specific role of glycogen synthase kinase 3 β in glucose homeostasis and insulin action. *Mol Cell Biol.* 2008; 28:6314–6328. [PubMed: 18694957]
109. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 β by phosphorylation: new kinase connections in insulin and growth-factor signalling. *Biochem J.* 1993; 296:15–19. [PubMed: 8250835]
110. Flotow H, Roach PJ. Synergistic phosphorylation of rabbit muscle glycogen synthase by cyclic AMP-dependent protein kinase and casein kinase I: implications for hormonal regulation of glycogen synthase. *J Biol Chem.* 1989; 264:9126–9128. [PubMed: 2498326]
111. Parker GJ, Lund KC, Taylor RP, McClain DA. Insulin resistance of glycogen synthase mediated by O-linked *N*-acetylglucosamine. *J Biol Chem.* 2003; 278:10022–10027. [PubMed: 12510058]
112. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, Yao J, Zhou L, Zeng Y, Li H, et al. Regulation of cellular metabolism by protein lysine acetylation. *Science.* 2010; 327:1000–1004. [PubMed: 20167786]
113. Bollen M. Combinatorial control of protein phosphatase-1. *Trends Biochem Sci.* 2001; 26:426–431. [PubMed: 11440854]
114. Ceulemans H, Bollen M. Functional diversity of protein phosphatase-1, a cellular economizer and reset button. *Physiol Rev.* 2004; 84:1–39. [PubMed: 14715909]
115. Tang PM, Bondor JA, Swiderek KM, DePaoli-Roach AA. Molecular cloning and expression of the regulatory (RG1) subunit of the glycogen-associated protein phosphatase. *J Biol Chem.* 1991; 266:15782–15789. [PubMed: 1651919]
116. Doherty MJ, Moorhead G, Morrice N, Cohen P, Cohen PT. Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein phosphatase-1. *FEBS Lett.* 1995; 375:294–298. [PubMed: 7498521]
117. Moorhead G, MacKintosh C, Morrice N, Cohen P. Purification of the hepatic glycogen-associated form of protein phosphatase-1 by microcystin–Sepharose affinity chromatography. *FEBS Lett.* 1995; 362:101–105. [PubMed: 7720853]
118. Doherty MJ, Cadefau J, Stalmans W, Bollen M, Cohen PT. Loss of the hepatic glycogen-binding subunit (GL) of protein phosphatase 1 underlies deficient glycogen synthesis in insulin-dependent diabetic rats and in adrenalectomized starved rats. *Biochem J.* 1998; 333:253–257. [PubMed: 9657963]
119. Doherty MJ, Young PR, Cohen PT. Amino acid sequence of a novel protein phosphatase 1 binding protein (R5) which is related to the liver- and muscle-specific glycogen binding subunits of protein phosphatase 1. *FEBS Lett.* 1996; 399:339–343. [PubMed: 8985175]
120. Printen JA, Brady MJ, Saltiel AR. PTG, a protein phosphatase 1-binding protein with a role in glycogen metabolism. *Science.* 1997; 275:1475–1478. [PubMed: 9045612]
121. Armstrong CG, Doherty MJ, Cohen PT. Identification of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1. *Biochem J.* 1998; 336:699–704. [PubMed: 9841883]
122. Armstrong CG, Browne GJ, Cohen P, Cohen PT. PPP1R6, a novel member of the family of glycogen-targeting subunits of protein phosphatase 1. *FEBS Lett.* 1997; 418:210–214. [PubMed: 9414128]
123. Munro S, Ceulemans H, Bollen M, Diplexcito J, Cohen PT. A novel glycogen-targeting subunit of protein phosphatase 1 that is regulated by insulin and shows differential tissue distribution in humans and rodents. *FEBS J.* 2005; 272:1478–1489. [PubMed: 15752363]
124. Luo X, Zhang Y, Ruan X, Jiang X, Zhu L, Wang X, Ding Q, Liu W, Pan Y, Wang Z, Chen Y. Fasting-induced protein phosphatase 1 regulatory subunit contributes to postprandial blood glucose homeostasis via regulation of hepatic glycogenesis. *Diabetes.* 2011; 60:1435–1445. [PubMed: 21471512]

125. Baskaran S, Roach PJ, DePaoli-Roach AA, Hurley TD. Structural basis for glucose-6-phosphate activation of glycogen synthase. *Proc Natl Acad Sci USA*. 2010; 107:17563–17568. [PubMed: 20876143]
126. Buschiazzo A, Ugalde JE, Guerin ME, Shepard W, Ugalde RA, Alzari PM. Crystal structure of glycogen synthase: homologous enzymes catalyze glycogen synthesis and degradation. *EMBO J*. 2004; 23:3196–3205. [PubMed: 15272305]
127. Horcajada C, Guinovart JJ, Fita I, Ferrer JC. Crystal structure of an archaeal glycogen synthase: insights into oligomerization and substrate binding of eukaryotic glycogen synthases. *J Biol Chem*. 2006; 281:2923–2931. [PubMed: 16319074]
128. Sheng F, Jia X, Yep A, Preiss J, Geiger JH. The crystal structures of the open and catalytically competent closed conformation of *Escherichia coli* glycogen synthase. *J Biol Chem*. 2009; 284:17796–17807. [PubMed: 19244233]
129. Johnson LN, Snape P, Martin JL, Acharya KR, Barford D, Oikonomakos NG. Crystallographic binding studies on the allosteric inhibitor glucose-6-phosphate to T state glycogen phosphorylase b. *J Mol Biol*. 1993; 232:253–267. [PubMed: 8331662]
130. Pederson BA, Cheng C, Wilson WA, Roach PJ. Regulation of glycogen synthase: identification of residues involved in regulation by the allosteric ligand glucose-6-P and by phosphorylation. *J Biol Chem*. 2000; 275:27753–27761. [PubMed: 10874034]
131. Johnson LN, Barford D. Glycogen phosphorylase: the structural basis of the allosteric response and comparison with other allosteric proteins. *J Biol Chem*. 1990; 265:2409–2412. [PubMed: 2137445]
132. Díaz A, Martínez-Pons C, Fita I, Ferrer JC, Guinovart JJ. Processivity and subcellular localization of glycogen synthase depend on a non-catalytic high affinity glycogen-binding site. *J Biol Chem*. 2011; 286:18505–18514. [PubMed: 21464127]
133. Baskaran S, Chikwana VM, Conreras CJ, Davis KD, Wilson WA, DePaoli-Roach AA, Roach PJ, Hurley TD. Multiple glycogen binding sites in eukaryotic glycogen synthase are required for high catalytic efficiency toward glycogen. *J Biol Chem*. 2011; 286:33999–4006. [PubMed: 21835915]
134. Cid E, Gomis RR, Geremia RA, Guinovart JJ, Ferrer JC. Identification of two essential glutamic acid residues in glycogen synthase. *J Biol Chem*. 2000; 275:33614–33621. [PubMed: 10924520]
135. Paladini AC, Leloir LF. Studies on uridine-diphosphate-glucose. *Biochem J*. 1952; 51:426–430. [PubMed: 12977745]
136. Weinstein DA, Correia CE, Saunders AC, Wolfsdorf JI. Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia. *Mol Genet Metab*. 2006; 87:284–288. [PubMed: 16337419]
137. Orho M, Bosshard NU, Buist NR, Gitzelmann R, Aynsley-Green A, Blumel P, Gannon MC, Nuttall FQ, Groop LC. Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0. *J Clin Invest*. 1998; 102:507–515. [PubMed: 9691087]
138. Irimia JM, Meyer CM, Peper CL, Zhai L, Bock CB, Previs SF, McGuinness OP, DePaoli-Roach A, Roach PJ. Impaired glucose tolerance and predisposition to the fasted state in liver glycogen synthase knock-out mice. *J Biol Chem*. 2010; 285:12851–12861. [PubMed: 20178984]
139. Kollberg G, Tulinius M, Gilljam T, Ostman-Smith I, Forsander G, Jotorp P, Oldfors A, Holme E. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. *N Engl J Med*. 2007; 357:1507–1514. [PubMed: 17928598]
140. Cameron JM, Levandovskiy V, MacKay N, Utgikar R, Ackerley C, Chiasson D, Halliday W, Raiman J, Robinson BH. Identification of a novel mutation in GYS1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts. *Mol Genet Metab*. 2009; 98:378–382. [PubMed: 19699667]
141. Pederson BA, Schroeder JM, Parker GE, Smith MW, DePaoli-Roach AA, Roach PJ. Glucose metabolism in mice lacking muscle glycogen synthase. *Diabetes*. 2005; 54:3466–3473. [PubMed: 16306363]
142. Pederson BA, Cope CR, Schroeder JM, Smith MW, Irimia JM, Thurberg BL, DePaoli-Roach AA, Roach PJ. Exercise capacity of mice genetically lacking muscle glycogen synthase: in mice,

- muscle glycogen is not essential for exercise. *J Biol Chem*. 2005; 280:17260–17265. [PubMed: 15711014]
143. McCue ME, Valberg SJ, Lucio M, Mickelson JR. Glycogen synthase 1 (GYS1) mutation in diverse breeds with polysaccharide storage myopathy. *J Vet Intern Med*. 2008; 22:1228–1233. [PubMed: 18691366]
144. Kacser H, Burns JA. Molecular democracy: who shares the controls? *Biochem Soc Trans*. 1979; 7:1149–1160. [PubMed: 389705]
145. Villar-Palasi C, Larner J. Insulin-mediated effect on the activity of UDPG-glycogen transglucosylase of muscle. *Biochim Biophys Acta*. 1960; 39:171–173. [PubMed: 13842294]
146. Ren JM, Marshall BA, Gulve EA, Gao J, Johnson DW, Holloszy JO, Mueckler M. Evidence from transgenic mice that glucose transport is rate-limiting for glycogen deposition and glycolysis in skeletal muscle. *J Biol Chem*. 1993; 268:16113–16115. [PubMed: 8344895]
147. Hansen PA, Gulve EA, Marshall BA, Gao J, Pessin JE, Holloszy JO, Mueckler M. Skeletal muscle glucose transport and metabolism are enhanced in transgenic mice overexpressing the Glut4 glucose transporter. *J Biol Chem*. 1995; 270:1679–1684. [PubMed: 7829503]
148. Kim YB, Peroni OD, Aschenbach WG, Minokoshi Y, Kotani K, Zisman A, Kahn CR, Goodyear LJ, Kahn BB. Muscle-specific deletion of the Glut4 glucose transporter alters multiple regulatory steps in glycogen metabolism. *Mol Cell Biol*. 2005; 25:9713–9723. [PubMed: 16227617]
149. Rossetti L, Stenbit AE, Chen W, Hu M, Barzilai N, Katz EB, Charron MJ. Peripheral but not hepatic insulin resistance in mice with one disrupted allele of the glucose transporter type 4 (*GLUT4*) gene. *J Clin Invest*. 1997; 100:1831–1839. [PubMed: 9312184]
150. Manchester J, Skurat AV, Roach P, Hauschka SD, Lawrence JC Jr. Increased glycogen accumulation in transgenic mice overexpressing glycogen synthase in skeletal muscle. *Proc Natl Acad Sci USA*. 1996; 93:10707–10711. [PubMed: 8855244]
151. Aschenbach WG, Suzuki Y, Breeden K, Prats C, Hirshman MF, Dufresne SD, Sakamoto K, Vilardo PG, Steele M, Kim JH, et al. The muscle specific protein phosphatase PP1G/RGL(GM) is essential for activation of glycogen synthase by exercise. *J Biol Chem*. 2001; 276:39959–39967. [PubMed: 11522787]
152. Suzuki Y, Lanner C, Kim JH, Vilardo PG, Zhang H, Yang J, Cooper LD, Steele M, Kennedy A, Bock CB, et al. Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL. *Mol Cell Biol*. 2001; 21:2683–2694. [PubMed: 11283248]
153. Delibegovic M, Armstrong CG, Dobbie L, Watt PW, Smith AJ, Cohen PT. Disruption of the striated muscle glycogen targeting subunit PPP1R3A of protein phosphatase 1 leads to increased weight gain, fat deposition, and development of insulin resistance. *Diabetes*. 2003; 52:596–604. [PubMed: 12606498]
154. Savage DB, Zhai L, Ravikumar B, Choi CS, Snaar JE, McGuire AC, Wou SE, Medina-Gomez G, Kim S, Bock CB, et al. A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice. *PLoS Med*. 2008; 5:e27. [PubMed: 18232732]
155. Zhai L, Choi CS, Irimia-Dominguez J, McGuire AC, Kim S, Bock CB, Roach PJ, Shulman GI, DePaoli-Roach AA. Enhanced insulin sensitivity and energy expenditure in PPP1R3C (PTG) deleted mice. *Diabetes*. 2007; 56(Suppl 1):A62.
156. Crosson SM, Khan A, Printen J, Pessin JE, Saltiel AR. *PTG* gene deletion causes impaired glycogen synthesis and developmental insulin resistance. *J Clin Invest*. 2003; 111:1423–1432. [PubMed: 12727934]
157. Shulman RG, Rothman DL. Enzymatic phosphorylation of muscle glycogen synthase: a mechanism for maintenance of metabolic homeostasis. *Proc Natl Acad Sci USA*. 1996; 93:7491–7495. [PubMed: 8755501]
158. Shulman RG, Bloch G, Rothman DL. *In vivo* regulation of muscle glycogen synthase and the control of glycogen synthesis. *Proc Natl Acad Sci USA*. 1995; 92:8535–8542. [PubMed: 7567971]
159. Chase JR, Rothman DL, Shulman RG. Flux control in the rat gastrocnemius glycogen synthesis pathway by *in vivo* $^{13}\text{C}/^{31}\text{P}$ NMR spectroscopy. *Am J Physiol Endocrinol Metab*. 2001; 280:E598–E607. [PubMed: 11254467]

160. Schafer JR, Fell DA, Rothman D, Shulman RG. Protein phosphorylation can regulate metabolite concentrations rather than control flux: the example of glycogen synthase. *Proc Natl Acad Sci USA*. 2004; 101:1485–1490. [PubMed: 14745035]
161. Atkinson DE. Limitation of metabolite concentrations and the solvent capacity of the living cell. *Curr Top Cell Regul*. 1969; 1:29–43.
162. Jucker BM, Barucci N, Shulman GI. Metabolic control analysis of insulin-stimulated glucose disposal in rat skeletal muscle. *Am J Physiol*. 1999; 277:E505–E512. [PubMed: 10484363]
163. Murphy E, Hellerstein M. Is in vivo nuclear magnetic resonance spectroscopy currently a quantitative method for whole-body carbohydrate metabolism? *Nutr Rev*. 2000; 58:304–314. [PubMed: 11127969]
164. Lawrence JC Jr, Roach PJ. New insights into the role and mechanism of glycogen synthase activation by insulin. *Diabetes*. 1997; 46:541–547. [PubMed: 9075792]
165. Hemmings BA, Yellowlees D, Kernohan JC, Cohen P. Purification of glycogen synthase kinase 3 from rabbit skeletal muscle: copurification with the activating factor (FA) of the (Mg-ATP) dependent protein phosphatase. *Eur J Biochem*. 1981; 119:443–451. [PubMed: 6273157]
166. Lizcano JM, Alessi DR. The insulin signalling pathway. *Curr Biol*. 2002; 12:R236–238. [PubMed: 11937037]
167. Woodgett JR. Recent advances in the protein kinase B signaling pathway. *Curr Opin Cell Biol*. 2005; 17:150–157. [PubMed: 15780591]
168. Pearce NJ, Arch JR, Clapham JC, Coghlan MP, Corcoran SL, Lister CA, Llano A, Moore GB, Murphy GJ, Smith SA, et al. Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3 β on a muscle-specific promoter. *Metabolism*. 2004; 53:1322–1330. [PubMed: 15375789]
169. Lawrence JC Jr, Hiken JF, DePaoli-Roach AA, Roach PJ. Hormonal control of glycogen synthase in rat hemidiaphragms: effects of insulin and epinephrine on the distribution of phosphate between two cyanogen bromide fragments. *J Biol Chem*. 1983; 258:10710–10719. [PubMed: 6411719]
170. Parker PJ, Caudwell FB, Cohen P. Glycogen synthase from rabbit skeletal muscle: effect of insulin on the state of phosphorylation of the seven phosphoserine residues *in vivo*. *Eur J Biochem*. 1983; 130:227–234. [PubMed: 6402364]
171. Skurat AV, Dietrich AD. Phosphorylation of Ser⁶⁴⁰ in muscle glycogen synthase by DYRK family protein kinases. *J Biol Chem*. 2004; 279:2490–2498. [PubMed: 14593110]
172. Kuma Y, Campbell DG, Cuenda A. Identification of glycogen synthase as a new substrate for stress-activated protein kinase 2b/p38 β . *Biochem J*. 2004; 379:133–139. [PubMed: 14680475]
173. Wilson WA, Skurat AV, Probst B, DePaoli-Roach AA, Roach PJ, Rutter J. Control of mammalian glycogen synthase by PAS kinase. *Proc Natl Acad Sci USA*. 2006; 102:16596–601. [PubMed: 16275910]
174. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, Alessi DR. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. *EMBO J*. 2005; 24:1571–1583. [PubMed: 15791206]
175. Nielsen JN, Richter EA. Regulation of glycogen synthase in skeletal muscle during exercise. *Acta Physiol Scand*. 2003; 178:309–319. [PubMed: 12864735]
176. Nielsen JN, Wojtaszewski JF. Regulation of glycogen synthase activity and phosphorylation by exercise. *Proc Nutr Soc*. 2004; 63:233–237. [PubMed: 15294036]
177. Shulman RG, Rothman DL. The “glycogen shunt” in exercising muscle: a role for glycogen in muscle energetics and fatigue. *Proc Natl Acad Sci USA*. 2001; 98:457–461. [PubMed: 11209049]
178. Wojtaszewski JF, Higaki Y, Hirshman MF, Michael MD, Dufresne SD, Kahn CR, Goodyear LJ. Exercise modulates postreceptor insulin signaling and glucose transport in muscle-specific insulin receptor knockout mice. *J Clin Invest*. 1999; 104:1257–1264. [PubMed: 10545524]
179. Hubbard MJ, Cohen P. Regulation of protein phosphatase-1G from rabbit skeletal muscle. 1. Phosphorylation by cAMP-dependent protein kinase at site 2 releases catalytic subunit from the glycogen-bound holoenzyme. *Eur J Biochem*. 1989; 186:701–709. [PubMed: 2558013]

180. Lai YC, Stuenkel JT, Kuo CH, Jensen J. Glycogen content and contraction regulate glycogen synthase phosphorylation and affinity for UDP-glucose in rat skeletal muscles. *Am J Physiol Endocrinol Metab.* 2007; 293:E1622–E1629. [PubMed: 17878227]
181. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. *Nat Rev Mol Cell Biol.* 2007; 8:774–785. [PubMed: 17712357]
182. Richter EA, Ruderman NB. AMPK and the biochemistry of exercise: implications for human health and disease. *Biochem J.* 2009; 418:261–275. [PubMed: 19196246]
183. Carling D, Hardie DG. The substrate and sequence specificity of the AMP-activated protein kinase: phosphorylation of glycogen synthase and phosphorylase kinase. *Biochim Biophys Acta.* 1989; 1012:81–86. [PubMed: 2567185]
184. Jorgensen SB, Nielsen JN, Birk JB, Olsen GS, Viollet B, Andreelli F, Schjerling P, Vaulont S, Hardie DG, Hansen BF, et al. The α 2-5'AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. *Diabetes.* 2004; 53:3074–3081. [PubMed: 15561936]
185. McBride A, Ghilagaber S, Nikolaev A, Hardie DG. The glycogen-binding domain on the AMPK β subunit allows the kinase to act as a glycogen sensor. *Cell Metab.* 2009; 9:23–34. [PubMed: 19117544]
186. Parker GJ, Koay A, Gilbert-Wilson R, Waddington LJ, Stapleton D. AMP-activated protein kinase does not associate with glycogen α -particles from rat liver. *Biochem Biophys Res Commun.* 2007; 362:811–815. [PubMed: 17767922]
187. Danforth WH. Glycogen synthase activity in skeletal muscle: interconversion of two forms and control of glycogen synthesis. *J Biol Chem.* 1965; 240:588–593. [PubMed: 14275108]
188. McBride A, Hardie DG. AMP-activated protein kinase: a sensor of glycogen as well as AMP and ATP? *Acta Physiol.* 2009; 196:99–113.
189. Milan D, Jeon JT, Looft C, Amarger V, Robic A, Thelander M, Rogel-Gaillard C, Paul S, Iannuccelli N, Rask L, et al. A mutation in *PRKAG3* associated with excess glycogen content in pig skeletal muscle. *Science.* 2000; 288:1248–1251. [PubMed: 10818001]
190. Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. *Circ Res.* 2007; 100:474–488. [PubMed: 17332438]
191. DePaoli-Roach AA, Tagliabracci VS, Segvich DM, Meyer CM, Irimia JM, Roach PJ. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to Lafora bodies and the accumulation of insoluble laforin. *J Biol Chem.* 2010; 285:25372–25381. [PubMed: 20538597]
192. Pederson BA, Wilson WA, Roach PJ. Glycogen synthase sensitivity to glucose-6-P is important for controlling glycogen accumulation in *Saccharomyces cerevisiae*. *J Biol Chem.* 2004; 279:13764–13768. [PubMed: 14742447]
193. Bouskila M, Hunter RW, Ibrahim AF, Delattre L, Pegg M, van Diepen JA, Voshol PJ, Jensen J, Sakamoto K. Allosteric regulation of glycogen synthase controls glycogen synthesis in muscle. *Cell Metab.* 2010; 12:456–466. [PubMed: 21035757]
194. Hanashiro I, Roach PJ. Mutations of muscle glycogen synthase that disable activation by glucose 6-phosphate. *Arch Biochem Biophys.* 2002; 397:286–292. [PubMed: 11795884]
195. Hunter RW, Treebak JT, Wojtaszewski JF, Sakamoto K. Molecular mechanism by which AMP-activated protein kinase activation promotes glycogen accumulation in muscle. *Diabetes.* 2011; 60:766–774. [PubMed: 21282366]
196. Friden J, Seger J, Ekblom B. Topographical localization of muscle glycogen: an ultrahistochemical study in the human vastus lateralis. *Acta Physiol Scand.* 1989; 135:381–391. [PubMed: 2467521]
197. Marchand I, Tarnopolsky M, Adamo KB, Bourgeois JM, Chorneyko K, Graham TE. Quantitative assessment of human muscle glycogen granules size and number in subcellular locations during recovery from prolonged exercise. *J Physiol.* 2007; 580:617–628. [PubMed: 17272352]
198. Nielsen J, Schroder HD, Rix CG, Ortenblad N. Distinct effects of subcellular glycogen localization on tetanic relaxation time and endurance in mechanically skinned rat skeletal muscle fibres. *J Physiol.* 2009; 587:3679–3690. [PubMed: 19470780]

199. Peter JB, Barnard RJ, Edgerton VR, Gillespie CA, Stempel KE. Metabolic profiles of three fiber types of skeletal muscle in guinea pigs and rabbits. *Biochemistry*. 1972; 11:2627–2633. [PubMed: 4261555]
200. Jungermann K, Kietzmann T. Zonation of parenchymal and nonparenchymal metabolism in liver. *Annu Rev Nutr*. 1996; 16:179–203. [PubMed: 8839925]
201. Bartels H, Vogt B, Jungermann K. Glycogen synthesis from pyruvate in the periportal and from glucose in the perivenous zone in perfused livers from fasted rats. *FEBS Lett*. 1987; 221:277–283. [PubMed: 3622767]
202. van Schaftingen E, Veiga-da-Cunha M, Niculescu L. The regulatory protein of glucokinase. *Biochem Soc Trans*. 1997; 25:136–140. [PubMed: 9056859]
203. Hers HG. The control of glycogen metabolism in the liver. *Annu Rev Biochem*. 1976; 45:167–189. [PubMed: 183599]
204. Kelsall IR, Munro S, Hallyburton I, Treadway JL, Cohen PT. The hepatic PP1 glycogen-targeting subunit interaction with phosphorylase a can be blocked by C-terminal tyrosine deletion or an indole drug. *FEBS Lett*. 2007; 581:4749–4753. [PubMed: 17870073]
205. Kelsall IR, Rosenzweig D, Cohen PT. Disruption of the allosteric phosphorylase a regulation of the hepatic glycogen-targeted protein phosphatase 1 improves glucose tolerance *in vivo*. *Cell Signalling*. 2009; 21:1123–1134. [PubMed: 19275933]
206. Zibrova D, Grempler R, Streicher R, Kauschke SG. Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes. *Biochem J*. 2008; 412:359–366. [PubMed: 18298402]
207. Cid E, Cifuentes D, Baque S, Ferrer JC, Guinovart JJ. Determinants of the nucleocytoplasmic shuttling of muscle glycogen synthase. *FEBS J*. 2005; 272:3197–3213. [PubMed: 15955076]
208. Wilson WA, Boyer MP, Davis KD, Burke M, Roach PJ. The subcellular localization of yeast glycogen synthase is dependent upon glycogen content. *Can J Microbiol*. 2010; 56:408–420. [PubMed: 20555403]
209. Ou H, Yan L, Osmanovic S, Greenberg CC, Brady MJ. Spatial reorganization of glycogen synthase upon activation in 3T3-L1 adipocytes. *Endocrinology*. 2005; 146:494–502. [PubMed: 15486231]
210. Prats C, Cadefau JA, Cusso R, Qvortrup K, Nielsen JN, Wojtaszewski JF, Hardie DG, Stewart G, Hansen BF, Ploug T. Phosphorylation-dependent translocation of glycogen synthase to a novel structure during glycogen resynthesis. *J Biol Chem*. 2005; 280:23165–23172. [PubMed: 15840572]
211. Prats C, Helge JW, Nordby P, Qvortrup K, Ploug T, Dela F, Wojtaszewski JF. Dual regulation of muscle glycogen synthase during exercise by activation and compartmentalization. *J Biol Chem*. 2009; 284:15692–15700. [PubMed: 19339242]
212. Fukuda T, Roberts A, Ahearn M, Zaal K, Ralston E, Plotz PH, Raben N. Autophagy and lysosomes in Pompe disease. *Autophagy*. 2006; 2:318–320. [PubMed: 16874053]
213. Geddes R, Jeyarathan P, Taylor JA. Molecular and metabolic aspects of lysosomal glycogen. *Carbohydr Res*. 1992; 227:339–349. [PubMed: 1499032]
214. Yang Z, Klionsky DJ. An overview of the molecular mechanism of autophagy. *Curr Top Microbiol Immunol*. 2009; 335:1–32. [PubMed: 19802558]
215. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. *Curr Opin Cell Biol*. 2010; 22:124–131. [PubMed: 20034776]
216. Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y. Dynamics and diversity in autophagy mechanisms: lessons from yeast. *Nat Rev Mol Cell Biol*. 2009; 10:458–467. [PubMed: 19491929]
217. Komatsu M, Ichimura Y. Selective autophagy regulates various cellular functions. *Genes Cells*. 2010; 32:431–436.
218. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. *Autophagy*. 2011; 7:279–296. [PubMed: 21189453]
219. Kotoulas OB, Kalamidas SA, Kondomerkos DJ. Glycogen autophagy. *Microsc Res Tech*. 2004; 64:10–20. [PubMed: 15287014]

220. Dawes, GS.; Shelley, HJ. Physiological aspects of carbohydrate metabolism in the foetus and newborn. In: Dickens, F.; Randle, PJ.; Whelan, WJ., editors. Carbohydrate Metabolism and Its Disorders. Academic Press; London: 1968. p. 87-116.
221. Raben N, Roberts A, Plotz PH. Role of autophagy in the pathogenesis of Pompe disease. *Acta Myol.* 2007; 26:45–48. [PubMed: 17915569]
222. Raben N, Hill V, Shea L, Takikita S, Baum R, Mizushima N, Ralston E, Plotz P. Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. *Hum Mol Genet.* 2008; 17:3897–3908. [PubMed: 18782848]
223. Raben N, Schreiner C, Baum R, Takikita S, Xu S, Xie T, Myerowitz R, Komatsu M, Van der Meulen JH, Nagaraju K, et al. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder: murine Pompe disease. *Autophagy.* 2010; 6:1078–1089. [PubMed: 20861693]
224. Wang Z, Wilson WA, Fujino MA, Roach PJ. Antagonistic controls of autophagy and glycogen accumulation by Snf1p, the yeast homolog of AMP-activated protein kinase, and the cyclin-dependent kinase Pho85p. *Mol Cell Biol.* 2001; 21:5742–5752. [PubMed: 11486014]
225. Wilson WA, Wang Z, Roach PJ. Systematic identification of the genes affecting glycogen storage in the yeast *Saccharomyces cerevisiae*: implication of the vacuole as a determinant of glycogen level. *Mol Cell Proteomics.* 2002; 1:232–242. [PubMed: 12096123]
226. Meley D, Bauvy C, Houben-Weerts JH, Dubbelhuis PF, Helmond MT, Codogno P, Meijer AJ. AMP-activated protein kinase and the regulation of autophagic proteolysis. *J Biol Chem.* 2006; 281:34870–34879. [PubMed: 16990266]
227. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, Taylor R, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. *Science.* 2011; 331:456–461. [PubMed: 21205641]
228. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol.* 2011; 13:132–141. [PubMed: 21258367]
229. Lee JW, Park S, Takahashi Y, Wang HG. The association of AMPK with ULK1 regulates autophagy. *PLoS ONE.* 2010; 5:e15394. [PubMed: 21072212]
230. Shang L, Chen S, Du F, Li S, Zhao L, Wang X. Nutrient starvation elicits an acute autophagic response mediated by Ulk1 dephosphorylation and its subsequent dissociation from AMPK. *Proc Natl Acad Sci USA.* 2011; 108:4788–4793. [PubMed: 21383122]
231. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. *Curr Opin Cell Biol.* 2010; 22:132–139. [PubMed: 20056399]
232. Cardell RR, Michaels JE, Hung JT, Cardell EL. SERGE, the subcellular site of initial hepatic glycogen deposition in the rat: a radioautographic and cytochemical study. *J Cell Biol.* 1985; 101:201–206. [PubMed: 4008528]
233. Bouju S, Lignon MF, Pietu G, Le Cunff M, Leger JJ, Auffray C, Dechesne CA. Molecular cloning and functional expression of a novel human gene encoding two 41–43 kDa skeletal muscle internal membrane proteins. *Biochem J.* 1998; 335:549–556. [PubMed: 9794794]
234. Geng J, Klionsky DJ. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. *EMBO Rep.* 2008; 9:859–864. [PubMed: 18704115]
235. Noda NN, Ohsumi Y, Inagaki F. Atg8-family interacting motif crucial for selective autophagy. *FEBS Lett.* 2010; 584:1379–1385. [PubMed: 20083108]
236. Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. *Int J Biochem Cell Biol.* 2004; 36:2503–2518. [PubMed: 15325588]
237. Le Grand JN, Chakrama FZ, Seguin-Py S, Fraichard A, Delage-Mourroux R, Jouvenot M, Boyer-Guittaut M. GABARAPL1 (GEC1): original or copycat? *Autophagy.* 2011; 7:1098–1107. [PubMed: 21597319]
238. Lafora GR, Glueck B. Beitrag zur histopathologie der myoklonischen epilepsie. *Z Gesamte Neurol Psychiatr.* 1911; 6:1–14.
239. Ramachandran N, Girard JM, Turnbull J, Minassian BA. The autosomal recessively inherited progressive myoclonus epilepsies and their genes. *Epilepsia.* 2009; 50(Suppl 5):29–36. [PubMed: 19469843]

240. Ganesh S, Puri R, Singh S, Mittal S, Dubey D. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. *J Hum Genet.* 2006; 51:1–8. [PubMed: 16311711]
241. Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the *EPM2A* and *NHLRC1* genes. *Hum Mutat.* 2009; 30:715–723. [PubMed: 19267391]
242. Ganesh S, Agarwala KL, Amano K, Suzuki T, Delgado-Escueta AV, Yamakawa K. Regional and developmental expression of *Epm2a* gene and its evolutionary conservation. *Biochem Biophys Res Commun.* 2001; 283:1046–1053. [PubMed: 11355878]
243. Denu JM, Stuckey JA, Saper MA, Dixon JE. Form and function in protein dephosphorylation. *Cell.* 1996; 87:361–364. [PubMed: 8898189]
244. Ganesh S, Agarwala KL, Ueda K, Akagi T, Shoda K, Usui T, Hashikawa T, Osada H, Delgado-Escueta AV, Yamakawa K. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. *Hum Mol Genet.* 2000; 9:2251–2261. [PubMed: 11001928]
245. Wang J, Stuckey JA, Wishart MJ, Dixon JE. A unique carbohydrate binding domain targets the Lafora disease phosphatase to glycogen. *J Biol Chem.* 2002; 277:2377–2380. [PubMed: 11739371]
246. Chan EM, Ackerley CA, Lohi H, Ianzano L, Cortez MA, Shannon P, Scherer SW, Minassian BA. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. *Hum Mol Genet.* 2004; 13:1117–1129. [PubMed: 15102711]
247. Wang W, Roach PJ. Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase. *Biochem Biophys Res Commun.* 2004; 325:726–730. [PubMed: 15541350]
248. Gentry MS, Downen RH 3rd, Worby CA, Mattoo S, Ecker JR, Dixon JE. The phosphatase laforin crosses evolutionary boundaries and links carbohydrate metabolism to neuronal disease. *J Cell Biol.* 2007; 178:477–488. [PubMed: 17646401]
249. Gentry MS, Pace RM. Conservation of the glucan phosphatase laforin is linked to rates of molecular evolution and the glucan metabolism of the organism. *BMC Evol Biol.* 2009; 9:138. [PubMed: 19545434]
250. Worby CA, Gentry MS, Dixon JE. Laforin: a dual specificity phosphatase that dephosphorylates complex carbohydrates. *J Biol Chem.* 2006; 281:30412–30418. [PubMed: 16901901]
251. Fernández-Sánchez ME, Criado-García O, Heath KE, García-Fojeda B, Medraño-Fernández I, Gomez-Garre P, Sanz P, Serratosa JM, Rodríguez de Córdoba S. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. *Hum Mol Genet.* 2003; 12:3161–3171. [PubMed: 14532330]
252. Lohi H, Ianzano L, Zhao XC, Chan EM, Turnbull J, Scherer SW, Ackerley CA, Minassian BA. Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. *Hum Mol Genet.* 2005; 14:2727–2736. [PubMed: 16115820]
253. Gentry MS, Worby CA, Dixon JE. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. *Proc Natl Acad Sci USA.* 2005; 102:8501–8506. [PubMed: 15930137]
254. Ganesh S, Tsurutani N, Suzuki T, Ueda K, Agarwala KL, Osada H, Delgado-Escueta AV, Yamakawa K. The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain. *Hum Mol Genet.* 2003; 12:2359–2368. [PubMed: 12915448]
255. Ianzano L, Zhao XC, Minassian BA, Scherer SW. Identification of a novel protein interacting with laforin, the *EPM2a* progressive myoclonus epilepsy gene product. *Genomics.* 2003; 81:579–587. [PubMed: 12782127]
256. Puri R, Suzuki T, Yamakawa K, Ganesh S. Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. *J Biol Chem.* 2009; 284:22657–22663. [PubMed: 19542233]
257. Solaz-Fuster MC, Gimeno-Alcañiz JV, Ros S, Fernández-Sánchez ME, García-Fojeda B, Criado García O, Vilchez D, Domínguez J, García-Rocha M, Sánchez-Piris M, et al. Regulation of

- glycogen synthesis by the laforin–malin complex is modulated by the AMP-activated protein kinase pathway. *Hum Mol Genet.* 2008; 17:667–678. [PubMed: 18029386]
258. Minassian BA, Ianzano L, Meloche M, Andermann E, Rouleau GA, Delgado-Escueta AV, Scherer SW. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. *Neurology.* 2000; 55:341–346. [PubMed: 10932264]
259. Wang W, Parker GE, Skurat AV, Raben N, Depaoli-Roach AA, Roach PJ. Relationship between glycogen accumulation and the laforin dual specificity phosphatase. *Biochem Biophys Res Commun.* 2006; 350:588–592. [PubMed: 17022935]
260. Chen, YT.; Burchell, A. Glycogen storage diseases. In: Scriver, CR.; Beaudet, AL.; Sly, WS.; Valle, D., editors. *The Metabolic and Molecular Bases of Inherited Disease.* McGraw-Hill; New York: 1995. p. 935-965.
261. Nakajima H, Hamaguchi T, Yamasaki T, Tarui S. Phosphofructokinase deficiency: recent advances in molecular biology. *Muscle Nerve.* 1995; 3:S28–S34. [PubMed: 7603524]
262. Raben N, Danon M, Lu N, Lee E, Shliselfeld L, Skurat AV, Roach PJ, Lawrence JC Jr, Musumeci O, Shanske S, et al. Surprises of genetic engineering: a possible model of polyglucosan body disease. *Neurology.* 2001; 56:1739–1745. [PubMed: 11425943]
263. Pederson BA, Csitkovits AG, Simon R, Schroeder JM, Wang W, Skurat AV, Roach PJ. Overexpression of glycogen synthase in mouse muscle results in less branched glycogen. *Biochem Biophys Res Commun.* 2003; 305:826–830. [PubMed: 12767905]
264. Wang Y, Liu Y, Wu C, Zhang H, Zheng X, Zheng Z, Geiger TL, Nuovo GJ, Zheng P. Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. *Cancer Cell.* 2006; 10:179–190. [PubMed: 16959610]
265. Wang W, Lohi H, Skurat AV, DePaoli-Roach AA, Minassian BA, Roach PJ. Glycogen metabolism in tissues from a mouse model of Lafora disease. *Arch Biochem Biophys.* 2007; 457:264–269. [PubMed: 17118331]
266. Vernia S, Heredia M, Criado O, Rodríguez de Córdoba S, García-Rovés PM, Cansell C, Denis R, Luquet S, Foufelle F, Ferré P, Sanz P. Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice. *Hum Mol Genet.* 2011; 20:2571–2584. [PubMed: 21493628]
267. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature.* 2006; 441:880–884. [PubMed: 16625205]
268. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. *Nature.* 2006; 443:780–786. [PubMed: 17051204]
269. Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, Rubinsztein DC. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. *Curr Top Dev Biol.* 2006; 76:89–101. [PubMed: 17118264]
270. Aguado C, Sarkar S, Korolchuk VI, Criado O, Vernia S, Boya P, Sanz P, Rodríguez de Córdoba S, Knecht E, Rubinsztein DC. Laforin, the most common protein mutated in Lafora disease, regulates autophagy. *Hum Mol Genet.* 2010; 19:2867–2876. [PubMed: 20453062]
271. Inoki K, Guan KL. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. *Hum Mol Genet.* 2009; 18:R94–R100. [PubMed: 19297407]
272. Kim J, Guan KL. Amino acid signaling in TOR activation. *Annu Rev Biochem.* 2010; 80:1001–1032. [PubMed: 21548787]
273. Blennow A, Nielsen TH, Baunsgaard L, Mikkelsen R, Engelsen SB. Starch phosphorylation: a new front line in starch research. *Trends Plant Sci.* 2002; 7:445–450. [PubMed: 12399179]
274. Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M, Ackerley CA, Jovic NJ, et al. Mutations in *NHLRC1* cause progressive myoclonus epilepsy. *Nat Genet.* 2003; 35:125–127. [PubMed: 12958597]
275. Freemont PS. RING for destruction? *Curr Biol.* 2000; 10:R84–R87. [PubMed: 10662664]
276. Chan EM, Andrade DM, Franceschetti S, Minassian B. Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B. *Adv Neurol.* 2005; 95:47–57. [PubMed: 15508913]
277. Vilchez D, Ros S, Cifuentes D, Pujadas L, Vallès J, García-Fojeda B, Criado-García O, Fernández-Sánchez E, Medraño-Fernández I, Domínguez J, et al. Mechanism suppressing

- glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. *Nat Neurosci.* 2007; 10:1407–1413. [PubMed: 17952067]
278. Worby CA, Gentry MS, Dixon JE. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). *J Biol Chem.* 2008; 283:4069–4076. [PubMed: 18070875]
279. Cheng A, Zhang M, Gentry MS, Worby CA, Dixon JE, Saltiel AR. A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease. *Genes Dev.* 2007; 21:2399–2409. [PubMed: 17908927]
280. Moreno D, Towler MC, Hardie DG, Knecht E, Sanz P. The laforin–malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase β subunits. *Mol Biol Cell.* 2010; 21:2578–2588. [PubMed: 20534808]
281. Romá-Mateo C, Solaz-Fuster MdC, Gimeno-Alcañiz JV, Dukhande V, Donderis J, Marina A, Criado O, Koller A, Rodríguez de Córdoba S, Gentry MS, Sanz P. Laforin, a dual specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser²⁵ by AMP-activated protein kinase. *Biochem J.* 2011; 439:265–75. [PubMed: 21728993]
282. Vernia S, Solaz-Fuster MC, Gimeno-Alcañiz JV, Rubio T, Garcia-Haro L, Foretz M, Rodríguez de Córdoba S, Sanz P. AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and accelerates its down-regulation by the laforin–malin complex. *J Biol Chem.* 2009; 284:8247–8255. [PubMed: 19171932]
283. Mittal S, Dubey D, Yamakawa K, Ganesh S. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. *Hum Mol Genet.* 2007; 16:753–762. [PubMed: 17337485]
284. Garyali P, Siwach P, Singh PK, Puri R, Mittal S, Sengupta S, Parihar R, Ganesh S. The malin–laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin–proteasome system. *Hum Mol Genet.* 2009; 18:688–700. [PubMed: 19036738]
285. Turnbull J, Wang P, Girard JM, Ruggieri A, Wang TJ, Draginov AG, Kameka AP, Pencea N, Zhao X, Ackerley CA, Minassian BA. Glycogen hyperphosphorylation underlies Lafora body formation. *Ann Neurol.* 2010; 68:925–933. [PubMed: 21077101]
286. Ganesh S, Delgado-Escueta AV, Sakamoto T, Avila MR, Machado-Salas J, Hoshii Y, Akagi T, Gomi H, Suzuki T, Amano K, et al. Targeted disruption of the *Epm2a* gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. *Hum Mol Genet.* 2002; 11:1251–1262. [PubMed: 12019206]
287. Turnbull J, Depaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, Piliguiian M, Roach PJ, Wang P, Ackerley CA, Minassian BA. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. *PLoS Genet.* 2011; 7:e1002037. [PubMed: 21552327]
288. Guerrero R, Vernia S, Sanz R, Abreu-Rodríguez I, Almaraz C, García-Hoyos M, Michelucci R, Tassinari CA, Riguzzi P, Nobile C, et al. A PTG variant contributes to a milder phenotype in Lafora disease. *PLoS ONE.* 2011; 6:e21294. [PubMed: 21738631]




Figure 1. Glycogen structure

(A) Polymerizing α -1,4-glycosidic linkages and a branching α -1,6-glycosidic linkage are shown. (B) The tiered model for glycogen organization in which inner B-chains on average carry two branches and the outer A-chains are unbranched. The black circle denotes glycogenin.



Figure 2. Glycogen particles

Shown are the well-established glycogen-associated proteins: the metabolic enzymes (mauve) glycogenin (GN), glycogen synthase (GS), phosphorylase (PH) and debranching enzyme (DBE); the protein kinases (red) phosphorylase kinase (PH kinase) and AMPK; the phosphatases (green) type 1 catalytic subunit (PP1c) and laforin (LF); the PP1 glycogen-targeting subunits (blue) R_{GL}, G_L and PTG; and the putative membrane-anchoring protein Stbd1. Malin has been suggested to bind glycogen via interaction with laforin. Phosphorylase kinase, Stbd1 and R_{GL} bind membranes. Numerous protein–protein interactions are either known or proposed to exist among these glycogen-binding proteins.




Figure 3. Overview of glycogen metabolism

Glc_{out}, extracellular glucose; Glc_{in}, intracellular glucose; HK, hexokinase; G6Pase, glucose-6-phosphatase; PGM, phosphoglucomutase; UP, UDP-glucose pyrophosphorylase; UGPPase, UDP-glucose pyrophosphatase; GN, glycogenin; GS, glycogen synthase; BE, branching enzyme; PH, glycogen phosphorylase; DBE, debranching enzyme; GAA, lysosomal α -glucosidase; GNG, gluconeogenesis.




Figure 4. Structure of mammalian glycogenin

(A) Ribbons representation of the glycogenin dimer. The active sites are denoted by the bound substrate UDP-glucose (magenta). The location of Tyr¹⁹⁵ near the dimer interface is indicated using magenta colouring of the residue. (B) The active site of glycogenin. Residues discussed in the text are labelled, and the position of the catalytically essential Mn²⁺ ion is shown using a purple sphere.




Figure 5. Regulatory features of glycogen synthase

Shown is a comparison of the general architecture of yeast and mammalian glycogen synthases in terms of phosphorylation sites (light blue, not to scale) and the arginine-rich cluster implicated in conferring sensitivity to activation by glucose 6-phosphate (green). The conserved arginine residues and the phosphorylated residues are in black and marked by dots. Some of the protein kinases involved in phosphorylating the mammalian enzyme are linked to sites they modify. See the legend to Table 2.




Figure 6. Ribbons diagram of eukaryotic glycogen synthase

The diagram highlights the sequence insertions and deletions of glycogen synthase that confer its allosteric regulation and preference for UDP-glucose. The secondary-structural elements conferring its tetrameric arrangement are coloured magenta. The location of the ten-residue deletion relative to the bacterial enzymes that conveys glucose 6-phosphate regulation is coloured blue. The inserted loop of residues that confer preference for UDP-glucose is coloured green.




Figure 7. Glucose 6-phosphate activation

The active sites of glycogen synthase are occluded in the absence of glucose 6-phosphate (A), but are opened and freed for glycogen access in the activated state (B). Glucose 6-phosphate is bound at the interface between subunits with multiple charged residues interacting with the phosphate moiety and relatively few contacts with the glucose moiety (C).




Figure 8. Interactions at the regulatory interface in different conformational states of yeast glycogen synthase

(A) The binding of glucose 6-phosphate reorganizes the interface and positions the regulatory helices approximately 12 Å apart. (B) One of the basal state conformations of yeast glycogen synthase where two sulfate molecules are bound next to Arg⁵⁸⁹ on the opposite face of the regulatory helix from where glucose 6-phosphate is bound. The regulatory helices are positioned approximately 8 Å apart in this conformation. (C) Another conformational state observed for glycogen synthase when a single sulfate molecule is bound between the regulatory helices and pulls the helices to within approximately 5 Å of one another. This state may resemble the inhibited phosphorylated state.




Figure 9. Maltodextran binding in glycogen phosphorylase and glycogen synthases
 (A) A ribbons representation of phosphorylase with a maltodextran bound in the ‘glycogen storage site’. (B) A ribbons representation of the glycogen synthase monomer from *E. coli* displaying maltodextran-binding sites ‘c’ and ‘d’ that are located on its N-terminal domain. (C) A ribbons representation of a single subunit in yeast glycogen synthase displaying the maltodextran bound to site-1 located in the N-terminal domain. (D) A ribbons representation of a single subunit of yeast glycogen synthase displaying the locations of all four maltodextran-binding sites.




Figure 10. Active site of yeast glycogen synthase

Those residues in Gys2p responsible for recognizing and binding the donor nucleotide sugar substrate are labelled. The glutamate residues present in the EX₇E motif probably participate in glucosyl transfer from the donor to acceptor substrate (Glu⁵⁰⁹) and in positioning the uridine ribose moiety (Glu⁵¹⁷).




Figure 11. Possible mechanism for glycogen phosphorylation

The usual glycogen synthase reaction is shown on the left where glucose from UDP-glucose is added to the non-reducing end to form a new α -1,4-glycosidic linkage. The proposed mechanism for the introduction of phosphate would involve the formation of either glucose-1,2-cyclic phosphate (a) or glucose-1,3-cyclic phosphate (b) in the enzyme active site. Reaction of C-1 of the cyclic phosphate would lead to addition of either a glucose 2-phosphate or a glucose 3-phosphate to the non-reducing end.




Figure 12. Control of glycogen synthesis in muscle

Both insulin and exercise increase glucose uptake via GLUT4. Increased glucose 6-phosphate (Glc-6-P) levels provide feedforward activation of GS (glycogen synthase). Insulin also causes dephosphorylation and activation of glycogen synthase by promoting the inactivation of GSK3 by Akt. The effect of exercise on glycogen synthase phosphorylation is more complex, potentially dephosphorylating via a PP1G containing R_{GL} and well as increasing phosphorylation via activation of protein kinases such as AMPK. PhK, phosphorylase kinase.




Figure 13. Degradation of glycogen

Glycogen is converted into glucose (Glc) by two pathways: (a) the classic cytosolic pathway controlled by cAMP and PKA, and mediated by glycogen phosphorylase (PH) and debranching enzyme (DBE); and (b) the lysosomal pathway in which degradation is ultimately catalysed by the lysosomal GAA. The latter pathway is poorly understood mechanistically, but probably resembles autophagy. It may be an example of selective autophagy with cargo specificity conferred by Stbd1 which would anchor glycogen to membranes and interact with the ATG8 family member GABARAPL1. The model also depicts the possibility that abnormally phosphorylated and/or branched glycogen is preferentially disposed of by this pathway. GS, glycogen synthase; LF, laforin.




Figure 14. Reported interactions among laforin, malin and glycogen-metabolizing proteins

The Figure summarizes some of the interactions reported for laforin and malin, as discussed in the text, based on studies *in vitro*, in cell systems and genetically modified mice. Blue single-headed arrows depict an enzyme–substrate relationship. Red double-headed arrows indicate a protein–protein interaction. Dashed green arrows indicate signalling pathways. Asterisks indicate some instances where analyses of *Epm2a*^{-/-} and/or *Epm2b*^{-/-} mice do not seem consistent with the proposed interaction. LF, laforin; LB; Lafora bodies; GS, glycogen synthase; DBE, debranching enzyme.

Table 1

Glucose and phosphate distribution within a glycogen particle

Tier*	Glucose/tier [†]	Chains/tier [‡]	Total glucose [§]	Phosphate/tier
1	13	1	13	0.03
2	26	3	39	0.08
3	52	7	91	0.2
4	104	15	195	0.4
5	208	31	403	0.8
6	416	63	819	1.6
7	832	127	1651	3.3
8	1664	255	3315	7
9	3328	511	6643	13
10	6656	1023	13299	27
11	13312	2047	26611	53
12	26624	4095	53235	106

* Based on the model of Figure 1.

[†] Based on a chain length of 13.

[‡] Number of chains per tier; chains(tier n) = $2^n - 1$

[§] Sum of the number of glucose residues up to and including this tier.

^{||} Covalent phosphates, assuming one phosphate per 500 glucose residues and an even distribution of phosphates between the inner and outer tiers. Total phosphates in a 12-tier molecule on this model would be ~212.

Table 2
Muscle glycogen synthase phosphorylation sites

CAMKII, Ca²⁺/calmodulin-dependent protein kinase II; CK1, protein kinase casein kinase 1; CK2, protein kinase CK2; DYRK, dual-specificity tyrosine-phosphorylated and -regulated kinase; PASK, PAS (Per/Arnt/Sim) domain-containing protein kinase; PhK, phosphorylase kinase; PKC, protein kinase C.

Phosphorylation site			
Common designation [*]	Residue (rabbit) [†]	Residue (mouse) [†]	<i>In vitro</i> kinase(s)
Site 2	7	8	AMPK, CAMKII, PhK, PKA, PKC
Site 2a	10	11	CK1
Site 3a	640	641	GSK3, PASK, DYRK
Site 3b	644	645	GSK3, p38 β
Site 3c	648	649	GSK3
Site 4	652	653	GSK3
Site 5	656	657	CK2
Site 1a	697	698	PKA, PKC
Site 1b	710	711	PKA, CAMKII

^{*}Site designations made before the protein sequence was known, but still used in many publications.

[†]Residue numbers were first derived from biochemical studies of rabbit muscle enzyme. More recent studies of mouse (and human) glycogen synthase generally follow HUGO recommendations that begin with the translational start site and thus differ by one. Both usages are present in the literature.